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Abstract Dysregulated gene expression contributes to most prevalent features in human
cancers. Here, we show that most subtypes of acute myeloid leukemia (AML) depend on the
aberrant assembly of MYB transcriptional co-activator complex. By rapid and selective
peptidomimetic interference with the binding of CBP/P300 to MYB, but not CREB or MLL1, we find
that the leukemic functions of MYB are mediated by CBP/P300 co-activation of a distinct set of
transcription factor complexes. These MYB complexes assemble aberrantly with LYL1, E2A, C/EBP
family members, LMO2, and SATB1. They are organized convergently in genetically diverse
subtypes of AML and are at least in part associated with inappropriate transcription factor co-
expression. Peptidomimetic remodeling of oncogenic MYB complexes is accompanied by specific
proteolysis and dynamic redistribution of CBP/P300 with alternative transcription factors such as
RUNX1 to induce myeloid differentiation and apoptosis. Thus, aberrant assembly and sequestration
of MYB:CBP/P300 complexes provide a unifying mechanism of oncogenic gene expression in AML.
This work establishes a compelling strategy for their pharmacologic reprogramming and
therapeutic targeting for diverse leukemias and possibly other human cancers caused by
dysregulated gene control.
Introduction
Gene dysregulation is one of the most prevalent features in human cancers (Bradner et al., 2017).
In many tumors, this is due to the pathogenic mutations of promoters, enhancers, and genes encod-
ing either transcription factors or factors that regulate chromatin and gene expression. In blood can-
cers, and acute myeloid leukemias (AML) in particular, aberrant gene expression is thought to
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contribute to most important properties of leukemia cells, including self-renewal, growth, and resis-
tance to therapy. For example, numerous pathogenic chromosomal translocations in AML, such as
those involving AML1 (RUNX1) and MLL1 (KMT2A) produce chimeric transcription or chromatin
remodeling factors that cause disease (Look, 1997). Consequently, therapeutic strategies aimed at
restoring normal gene expression are compelling because of their ability to target the causal molec-
ular processes and induce leukemia cell differentiation and elimination, leading in principle to dura-
ble disease control.
While specific molecular dependencies have been identified for some genetic subtypes of AML,
such as DOT1L or Menin inhibition for MLL-rearranged leukemias (Krivtsov et al., 2019), and
CARM1 inhibition for AML1-rearranged leukemias (Greenblatt et al., 2019), distinct pathogenetic
mechanisms of diverse AML subtypes also appear to converge on shared molecular pathways. For
example, approximately 25% of adult and childhood AMLs, including both MLL-rearranged and non-
rearranged cases, require aberrant activation of the transcription factor MEF2C, conferring suscepti-
bility to MARK and SIK inhibitors, which are currently being explored for clinical trials for patients
(Brown et al., 2018; Tarumoto et al., 2018; Vakoc and Kentsis, 2018). Similarly, nearly 50% of
examined AML specimens exhibit aberrant activation of HGF/MET/FGFR signaling (Kentsis et al.,
2012) and are being currently targeted therapeutically in the ongoing clinical trial of combined MET
and FGFR inhibitors in patients with relapsed or refractory AML (ClinicalTrials.gov Identifier
NCT03125239). Even for therapies targeting leukemogenic proteins directly, such as inhibitors of
IDH1/2, FLT3, KIT, SYK, as well as epigenetic and apoptotic therapies such as decitabine and vene-
toclax, their therapeutic efficacy and resistance depend on the underlying gene expression pheno-
typic states of AML cells (Tyner et al., 2018). Thus, there is intense interest in defining shared
molecular dependencies controlling leukemogenic gene expression in AML that can provide effec-
tive therapeutic options for patients.
Recently, MYB has emerged as a therapeutic target in AML, as transient suppression of Myb
nearly completely eliminates leukemia development in mouse models in vivo while sparing normal
hematopoietic cells (Zuber et al., 2011). Indeed, pioneering studies have implicated Myb as a key
mediator of leukemias (Klempnauer and Bishop, 1984; Luger et al., 2002). MYB is the cellular
homologue of the viral v-Myb oncogene that can cause avian leukemias and function as a pioneer
transcription factor in mammalian cells (Biedenkapp et al., 1988). MYB functions as a master regula-
tor of gene expression in diverse cell types, including hematopoietic cells where it controls cell pro-
liferation and differentiation (Ramsay and Gonda, 2008). Both mutations and translocations of MYB
have causal roles in various human malignancies, including leukemias. For example, aberrant expres-
sion of TAL1 in T-cell acute lymphoid leukemia (T-ALL) is induced by pathogenic somatic mutations
that create neomorphic MYB-binding sites (Mansour et al., 2014). Likewise, MYB is recurrently rear-
ranged in distinct subtype of blastic plasmacytoid dendritic cell neoplasms (BPDCN), a highly refrac-
tory hematologic malignancy (Suzuki et al., 2017).
Notably, the Booreana strain of mice that impairs the binding of Myb by its co-activator CBP/
P300 (Crebbp/Ep300) due to the mutation of Myb E308G in its transcriptional activation domain is
resistant to leukemogenesis induced by the otherwise fully penetrant MLL-AF9 and AML1-ETO onco-
genes but has largely normal hematopoiesis (Pattabiraman et al., 2014). Altogether, these findings
indicate that MYB and its co-factor CBP/P300 are fundamentally dysregulated in AML, presumably
through disordered gene expression that characterizes most forms of this disease. However, the
specific details of this mechanism remain poorly understood, largely due to the lack of suitable
tools.
Recently, we developed a peptidomimetic inhibitor of MYB:CBP/P300 (Ramaswamy et al.,
2018). Here, we report its second-generation version that has significantly increased potency, and
consequently suppresses leukemic MYB functions in most AML subtypes tested, while relatively spar-
ing normal hematopoietic progenitor cells. By rapid and selective peptidomimetic interference with
the binding of CBP/P300 to MYB, but not CREB or MLL1, we find that the leukemic functions of
MYB are mediated by CBP/P300-mediated co-activation of a distinct set of transcriptional factor
complexes that are aberrantly assembled with MYB in AML cells, which is associated at least in part
with their inappropriate expression. This therapeutic remodeling is accompanied by dynamic redistri-
bution of CBP/P300 complexes to genes that control cellular differentiation and growth. These find-
ings provide a unifying mechanism of oncogenic gene control, involving aberrant assembly of
transcription factor complexes and sequestration of CBP/P300 to promote oncogenic gene
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expression and block cellular differentiation. This paradigm should apply to other human cancers
caused by dysregulated gene control, elucidate specific molecular determinants of leukemia patho-
genesis, and enable the development of definitive therapies for patients.
Results
Genome-wide CRISPR screen identifies CBP requirement for the
susceptibility of AML cells to peptidomimetic blockade of MYB:CBP/
P300
In prior work, we used genetic and structural evidence to design a peptidomimetic inhibitor of the
MYB:CBP/P300 transcription coactivation complex, termed MYBMIM (Ramaswamy et al., 2018). To
elucidate its mechanisms of action in an unbiased manner, we carried out a genome-wide CRISPR
knockout screen to identify genes whose depletion affects the susceptibility of AML cells to MYB-
MIM. We used MOLM13 cells stably expressing Cas9 and transduced them with lentiviruses encod-
ing the genome-wide GeCKOv2 library at a multiplicity of infection of 0.3 (Figure 1A). Following
selection of transduced cells, we treated them with MYBMIM or PBS control in independent biologi-
cal replicates, and quantified the enrichment and depletion of cell clones expressing specific sgRNAs
by DNA sequencing of lentiviral barcodes (Figure 1A). This screen revealed a variety of genes whose
depletion confers relative resistance and susceptibility to MYBMIM treatment, consistent with the
presence of diverse cellular pathways that regulate oncogenic gene expression (Supplementary file
2a). The most significantly affected gene whose depletion was required to confer resistance to MYB-
MIM was CBP (Figure 1B). In contrast, CBP depletion exhibited no enrichment upon PBS treatment
(Figure 1—figure supplement 1). Thus, MYBMIM is a specific inhibitor of MYB:CBP, and emphasizes
the exquisite specificity of peptidomimetic inhibitors as pharmacologic modulators of protein
interactions.
CRYBMIM is a peptidomimetic chimera that specifically binds CBP/P300
KIX domain
Of all the functional genetic dependencies examined to date, the transcription factor MYB demon-
strates the broadest dependency across diverse AML subtypes, as compared to other non-hemato-
poietic cancers (Tarumoto et al., 2018). To generalize this analysis, we queried 688 human cancer
cell lines tested as part of the DepMap Cancer Dependency Map to identify genes that are selec-
tively required for the growth and survival of leukemia as compared to other cancer types. We found
that MYB is the most significantly required human gene in 37 leukemia cell lines, including 20 AML
cell lines, of diverse molecular subtypes (p=1.1e-15; Figure 2A).
MYB target gene activation requires its specific interaction with CREB-binding protein (CBP)/
P300 for co-activation (Dai et al., 1996). The helical MYB transactivation domain comprising residues
293–310 binds to the KIX domain of CBP/P300 (Zor et al., 2004). Using molecular mechanics simula-
tions, we previously developed a peptidomimetic inhibitor of this interaction, termed MYBMIM
(Ramaswamy et al., 2018). MYBMIM uses stereoselective substitution of D-amino acids to confer
proteolytic stability, and the cationic TAT domain for cell penetration. As a result, MYBMIM can spe-
cifically inhibit MYB:CBP/P300 binding in cells, but its activity is less pronounced in non-MLL-rear-
ranged AML cells (Ramaswamy et al., 2018). Given that MYBMIM bound to recombinant CBP KIX
domain with the dissociation constant of 21.3 ± 2.9 mM, as compared to the native MYB peptide of
4.2 ± 0.5 mM (Ramaswamy et al., 2018), we reasoned that a peptidomimetic inhibitor with higher
affinity to CBP/P300 would be more effective.
Consequently, we used molecular modeling to extend MYBMIM into the adjoining binding site
that binds CREB (Radhakrishnan et al., 1997; Cheng et al., 2008). We appended CREB residues
124–147 to MYBMIM, while replacing the EKIRK motif to maintain favorable backbone geometry, as
confirmed by molecular energy minimization calculations in implicit solvent (Figure 2B and C and
Figure 2—figure supplement 1). Termed CRYBMIM, this design preserves key MYB residues impli-
cated in leukemic transformation, including E308 which forms a salt bridge with CBP, while including
the pS133-containing portion of CREB that is responsible for its high-affinity binding to CBP
(Zor et al., 2004; Cheng et al., 2008; Radhakrishnan et al., 1997). Similarly, we also designed two
additional peptidomimetic inhibitors targeting the distinct CREB and MLL1-binding sites that are
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proximal to but non-overlapping with the MYB-binding site, termed CREBMIM and MLLMIM,
respectively (Figure 2B and C and Figure 2—figure supplement 1A–C).
As expected, both CRYBMIM and CREBMIM bind to the purified recombinant CBP KIX domain
with significantly improved (three– to six-fold) affinities as compared to MYBMIM and measured by
microscale thermophoresis (Kd of 5.7 ± 0.2 mM, 2.9 ± 0.7 mM, and 17.3 ± 1.6 mM, p=1e-15;
Figure 2D). To confirm these peptides can bind the CBP/P300 complex from cells, we immobilized
biotinylated CRYBMIM and CREBMIM peptides on streptavidin beads and used them to affinity
purify CBP/P300 from non-denatured nuclear extracts of MV411 AML cells. Consistently, we
observed efficient binding of nuclear CBP/P300 to peptide-conjugated but not control streptavidin
Figure 1. CBP depletion is required to confer resistance to MYBMIM in AML cells. (A) Schematic of the genome-wide CRISPR screen to identify genes
whose loss modifies MYBMIM effects in MOLM13 cells expressing Cas9. Cells were transduced with the GeCKOv2 library expressing single sgRNAs at
low multiplicity of infection, followed by 3-day treatment with 10 mM MYBMIM versus PBS control, with the sgRNA representation assessed by DNA
sequencing. (B) Volcano plot showing the relative abundance of cell clones expressing sgRNAs targeting specific genes (fold change of MYBMIM-
treated cells at T1 versus T0) and their statistical significance from biological replicates. Dashed line represents no enrichment, with positive values
representing genes whose depletion confers relative resistance to MYBMIM. CBP is marked in red.
The online version of this article includes the following source data and figure supplement(s) for figure 1:
Source data 1. Genome-wide CRISPR knockout screen (GeCKO) gene summary.
Figure supplement 1. CBP depletion is dispensable in AML cells.
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Figure 2. CRYBMIM is an improved peptidomimetic chimera that specifically binds the KIX domain of CBP/P300 in vitro and in cells. (A) Heatmap of
the top 10 and bottom 10 gene dependencies for survival and proliferation of 652 cancer cell lines in the DepMap Cancer Dependency Map Project,
ranked by the greatest dependency for 37 leukemia lines, 20 of which are AML cell lines, as indicated by the red color gradient; *p=1.1e-15, t-test of
leukemia versus other tumor types. (B) Retro-inverso amino acid sequences of MYBMIM, CREBMIM and CRYBMIM, with amino acids derived from MYB,
Figure 2 continued on next page
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beads (Figure 2E). We found that increasing concentrations of free CRYBMIM could compete with
the binding of CBP/P300 to immobilized CRYBMIM, with the apparent Ki of approximately 4.7 mM
based on quantitative fluorescence densitometry measurements (Figure 2F). We confirmed the
specificity of this binding by incubating bound complexes with 100-fold excess of TAT control pepti-
des, which demonstrated no measurable displacement as compared to PBS control (Figure 2E–F). In
contrast, excess CREBMIM was significantly less effective at displacing CBP/P300 from immobilized
CREBMIM (apparent Ki >100 mM, Figure 2E–F), consistent with the much higher nM affinity and allo-
steric effects that characterize the CREB:CBP/P300 interaction (Goto et al., 2002;
Radhakrishnan et al., 1997). This is also consistent with the presence of distinct CBP transcription
factor complexes in AML cells, some of which (MYB) are susceptible to peptidomimetic blockade,
and others (CREB) exhibiting more stable interactions. Importantly, CRYBMIM binds CBP/P300 spe-
cifically, as exposure of AML cell extracts to streptavidin-immobilized biotinylated CRYBMIM leads
to efficient binding to CBP/P300, but not MED15 which is highly expressed in MV411 AML cells and
contains a known KIX domain with the closest sequence similarity to CBP/P300 (38% identity; Fig-
ure 2—figure supplement 1D–E). Thus, CRYBMIM is a specific high-affinity inhibitor of MYB:CBP/
P300 binding.
Potent and broad-spectrum activity of CRYBMIM against diverse
subtypes of AML
To confirm that CRYBMIM maintains effective cell penetration and nuclear accumulation in AML
cells, we studied its fluorescein isothiocyanate (FITC)-conjugated derivative using live cell confocal
fluorescence microscopy (Figure 3A). Consistently, we observed that both FITC-CRYBMIM and
FITC-CREBMIM efficiently localized to the nuclei of MV411 AML cells within 1 hr of peptide treat-
ment (Figure 3A). We confirmed specific nuclear accumulation of CRYBMIM as opposed to non-spe-
cific membrane binding that can affect TAT-containing peptides by confocal subcellular imaging of
cells co-stained with specific mitochondrial and nuclear dyes (Figure 3A).
Previously, we observed that MYBMIM blocks the binding of MYB to CBP/P300 in AML cells,
requiring relatively high 20 mM concentrations for 3 hr to achieve this effect (Ramaswamy et al.,
2018). To ascertain whether CRYBMIM can achieve more potent interference with the binding of
MYB to the CBP/P300 complex in cells due to its improved affinity as compared
to MYBMIM (Figure 2D), we treated MV411 cells with 10 mM peptides for 1 hr and immunoprecipi-
tated CBP/P300 using specific antibodies (Figure 3B). Under these more stringent conditions, we
found that CRYBMIM is indeed more potent compared to MYBMIM, as evidenced by the substantial
depletion of MYB from the immunoprecipitated CBP/P300 complex by CRYBMIM but not MYBMIM
under these conditions (Figure 3B).
This effect was specific because the inactive analogue of CRYBMIM, termed CG3, in which three
key residues have been replaced with glycines (Supplementary file 1a), was unable to compete with
MYB:CBP/P300 binding in cells, an effect observed with CBP/P300-specific but not control isotype
non-specific antibodies (Figure 3B). Neither CREBMIM nor CRYBMIM treatment interfered with the
binding of CREB to the cellular CBP/P300 complex (Figure 3B), in agreement with the affinities of
their direct binding to the recombinant CBP KIX domain (Figure 2D–F), the nM affinity of CREB:
CBP/P300 interaction (Radhakrishnan et al., 1997), and the specific molecular features required for
MYB but not CREB or MLL1 binding (Figure 2C and Figure 2—figure supplement 1).
Figure 2 continued
CREB, and TAT marked in blue, green, and black, respectively. (C) Molecular model of the CRYBMIM:KIX complex. Residues making contact with KIX
are labeled, with portions derived from MYB and CREB marked in blue and green, respectively. (D) Binding of FITC-conjugated CREBMIM (blue),
CRYBMIM (red), and MYBMIM (black), as measured using microscale thermophoresis; Kd = 2.9 ± 0.7, 5.7 ± 0.2, and 17.3 ± 1.6, respectively. Error bars
represent standard deviations of three biological replicates; p<1e-15, ANOVA, for CRYBMIM versus MYBMIM. (E) Western blot showing binding of
nuclear CBP/P300 isolated from AML cells to biotinylated CRYBMIM or CREBMIM, specifically competed by the excess free peptides as indicated. (F)
Quantification of CBP/P300 binding to CRYBMIM and CREBMIM by fluorescence densitometry, with black, gray, and red denoting PBS control, TAT
control, and peptide competition, respectively.
The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. Molecular models of CREB and MLL structures in complex with CBP KIX, and CRYBMIM selectively binds to KIX domain in CBP/
P300.
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Figure 3. Potent and broad-spectrum activity of CRYBMIM against diverse AML cell lines but relatively sparing of normal hematopoietic progenitor
cells. (A) Representative live cell confocal microscopy images of MV411 cells treated with 100 nM FITC-conjugated peptides as indicated for 1 hr,
counterstained with Mitotracker (red) and Hoechst 33342 (blue). Scale bar indicates 20 mm, with z-stack of 1.5 mm. (B) Western blots showing
immunoprecipitated nuclear CBP/P300 co-purified with MYB and CREB from MV411 cells treated with 10 mM peptides as indicated for 1 hr. (C–D) Cell
viability of MV411 cells as a function of increasing concentrations of 48 hr peptide treatment, comparing (C) CRYBMIM to MYBMIM, CREBMIM and
MLLMIM (IC50 = 6.88 ± 3.39, 13.1 ± 3.3 29.15 ± 3.79, and 24.22 ± 2.00, p<1e-15, ANOVA); (D) TG3 and CG3 (IC50 = 16.65 ± 1.00 and 48.91 ± 2.55, p<1e-
15, ANOVA). Error bars represent standard deviation of three biological replicates. (E) Colony forming ability of CD34+ cells isolated from human
Figure 3 continued on next page
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To test the prediction that higher affinity binding of CRYBMIM to CBP/P300 would translate into
improved anti-leukemia potency, we assessed its effects on the viability of cultured human leukemia
and normal hematopoietic cells. Consistent with this prediction, we observed that CRYBMIM exhib-
ited significantly higher potency against MV411 AML cells, as compared to MYBMIM as well as
CREBMIM and MLLMIM (IC50 = 6.9 ± 3.4 mM, 13 ± 3.3, 29 ± 3.8 mM, and 24 ± 2.0 mM, p=1e-15;
Figure 3C). We confirmed CRYBMIM’s specificity by analyzing its inactive analogue CG3 and MYB-
MIM’s inactive analogue TG3, in which three residues forming key electrostatic and hydrophobic
interactions with the KIX domain were replaced by glycines; both exhibited significantly reduced
activity (IC50 of 17 ± 1.0 mM and 49 ± 2.6 mM, p=2.75e-4 and <1e-15, respectively; Figure 3D). To
assess the effects of CRYBMIM on normal hematopoietic progenitor cells, we used primary human
CD34+ umbilical cord progenitor cells, cultured in serum-free medium in methylcellulose, as well as
in liquid culture (Figure 3—figure supplement 1D). We observed minimal effects on the clonogenic
growth of normal progenitor cells, as compared to that of MV411 AML cells which was significantly
suppressed (91 ± 3.8% versus 47 ± 2.4% colonies, p=1e-4; Figure 3E and Figure 3—figure supple-
ment 1A). Extending the duration of treatment led to small reduction of myeloid/granulocyte pro-
genitors, and an increase in erythroid progenitor colony-forming units (70.5 ± 5.6% and 112.3 ±
2.2%, respectively; Figure 3F). In contrast, doxorubicin, which is commonly used to treat AML,
caused significant and substantial impairments in the clonogenic capacity of all hematopoietic pro-
genitor cells (Figure 3—figure supplement 1B–C). Thus, CRYBMIM exhibits improved anti-leukemia
activity, while relatively sparing normal blood cells.
Importantly, CRYBMIM achieved significantly improved, logarithmic suppression of growth and
survival of most AML cell lines tested, as compared to MYBMIM and CREBMIM (Figure 3G). For
example, whereas MYBMIM induced nearly 100-fold suppression of growth of MV411 cells after 6
days of treatment in agreement with prior studies (Ramaswamy et al., 2018), CRYBMIM achieved
more than 1000-fold suppression compared to control (p=8.6e-3; Figure 3G), consistent with its
improved biochemical affinity (Figure 2D). This improved activity of CRYBMIM spanned diverse AML
subtypes, including MLL-rearranged, AML1-ETO translocated, PML-RARA-translocated, DNMT3A-
mutant, NPM1c-mutant, TP53-mutant, MYC-amplified, and WT1-mutant cell lines, with the excep-
tion of erythroblastic BCR-ABL1-translocated K562 cells (10 of 11 cell lines tested; Figure 3G and
Supplementary file 1b). In contrast, under these conditions, CRYBMIM had no significant effects on
the growth and differentiation of normal human umbilical cord blood progenitor cells in vitro
(Figure 3E and F and Figure 3—figure supplement 1A). Interestingly, CRYBMIM also exhibited
anti-tumor effects on various solid tumor cell lines, including some medulloblastoma, neuroblastoma,
and breast carcinoma cells, at least some of which also exhibit high levels of MYB expression and
genetic dependence (Figure 3—figure supplement 2A–B). In all, CRYBMIM has broad-spectrum
activity against diverse subtypes of AML, while relatively sparing normal hematopoietic cells.
CBP is specifically required for susceptibility of AML cells to
peptidomimetic MYB blockade
CBP and EP300 are closely related transcriptional coactivators with distinct activities in cells. To pre-
cisely define their contributions, we used CRISPR interference to elucidate their requirements for
susceptibility to CRYBMIM (Figure 4A). We used MV411, MOLM13, OCIAML3, and K562 AML cells
that stably express Cas9 and transduced them with mCherry or GFP-expressing lentiviruses encod-
ing specific and independent sgRNAs targeting CBP and EP300, as compared to the AAVS1 safe
Figure 3 continued
umbilical cord blood (CD34+ CB, gray) and MV411 AML (red) cells following CRYBMIM or MYBMIM treatment. Data represent three biological
replicates; *p=7.4e-5, t-test of normal CD34+ CB versus MV411 AML cells. (F) Preservation of clonogenic capacity of CD34+ CB cells in differentiating
into erythroid blast forming units (BFU-E, light gray) and granulocyte macrophage colony forming units (CFU-GM, gray) as a function of CRYBMIM
treatment. (G) Cell viability of AML cell lines treated with control PBS (black), 20 mM CREBMIM (blue), MYBMIM (gray), or CRYBMIM (red) as indicated
for 6 days with media replacement every 48 hr in three biological replicates (p=8.6e-3, t-test for CRYBMIM versus control).
The online version of this article includes the following figure supplement(s) for figure 3:
Figure supplement 1. CRYBMIM relatively spares normal hematopoietic progenitor cells in vitro.
Figure supplement 2. Activity of CRYBMIM on non-hematopoietic cells.
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Figure 4. CBP but not P300 is dispensable for the growth and survival of AML cells, and is required for the susceptibility to peptidomimetic MYB
blockade by CRYBMIM. (A) Schematic of the competitive assays to define specific genetic dependencies. AML cells expressing Cas9 and GFP are
transduced with sgRNAs targeting specific genes and expressing mCherry, followed by quantitation of cell abundance by fluorescence activated cell
scanning (FACS) of GFP and mCherry-expressing cells. (B) Western blots demonstrating specific depletion of CBP in MV411 (left) and MOLM13 (right)
Figure 4 continued on next page
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harbor locus and CDK1 that is required for cell survival, as negative and positive controls, respec-
tively. We confirmed specific depletion of the majority of CBP protein by Western immunoblotting
in cells expressing sgCBP-1 and sgCBP-2 with intact EP300 expression, but not those not transduced
with sgRNA lentiviruses or those expressing sgNEG-1 and sgNEG-2 (Figure 4B). We found that
depletion of EP300 caused gradual decrease in cell proliferation over 3–6 days (Figure 4—figure
supplement 1A–C), whereas depletion of CDK1 caused acute cell cycle arrest and apoptosis (Fig-
ure 4—figure supplement 1A–C). In contrast, depletion of CBP had no significant effects on steady-
state cell fitness, but caused significant resistance to CRYBMIM, where CBP-deficient cells outcom-
peted their non-transduced counterparts when treated with CRYBMIM (p=6.0e-10 and 4.0e-8 for
sgCBP-1 and sgCBP-2 in MOLM13 cells, respectively, and 1.1e-6 and 3.7e-6 for MV411 cells;
Figure 4C–D). In contrast, K562 cells that are mostly resistant to CRYBMIM exhibited selective fit-
ness upon depletion of EP300 (Figure 4—figure supplement 1D). This suggests that CBP and
EP300 contribute to distinct gene expression programs, presumably as part of specific transcription
factor complexes, as required for their susceptibility to peptidomimetic blockade.
CRYBMIM blocks oncogenic MYB gene expression and restores normal
myeloid cell differentiation
The assembly of MYB with CBP/P300 controls gene expression in part due to its transcriptional co-
activation at specific enhancers and promoters (Kasper et al., 2010; Zhao et al., 2011). Previously,
we found that MYBMIM can suppress MYB:CBP/P300-dependent gene expression, leading to AML
cell apoptosis that required MYB-mediated suppression of BCL2 (Ramaswamy et al., 2018). How-
ever, because MYBMIM’s suppression of gene expression was accompanied mostly by apoptosis,
we were unable to discern the molecular mechanisms that directly dysregulate the activity of the
CBP/P300 transcription factor complex in AML cells.
Given that CRYBMIM has increased affinity for CBP/P300 similar to that of native MYB (5.7 ± 0.2
mM and 4.2 ± 0.5 mM, respectively), we reasoned that its improved activity would now permit
detailed kinetic studies to define the specific gene expression programs that are aberrantly activated
in AML cells. Consistent with this prediction, comparison of the effects of CRYBMIM on gene expres-
sion and consequent apoptosis of MV411 cells revealed that 1 and 4 hr exposures led to significant
changes in gene expression with minimal induction of apoptosis (Figure 5—figure supplement 1).
Thus, we used RNA-sequencing (RNA-seq) to define the changes on gene expression genome-wide
upon 1 and 4 hr exposures to CRYBMIM as compared to PBS control (Figure 5A–B). We found that
after 4-hr duration of treatment, CRYBMIM causes significant downregulation of 2869 genes, includ-
ing known MYB target genes MYC, IKZF1, GATA2, and KIT (Figure 5A–C, Supplementary file 2b-
e). Similar to MYBMIM, CRYBMIM also caused significant upregulation of distinct genes, an effect
that was substantially more pronounced upon 4 hr of treatment (4099 genes; 5A-B,
Supplementary file 2b-e). Interestingly, in addition to the expected suppression of MYB target
genes (Figure 5C), gene set enrichment analysis also revealed significant induction of myeloid and
monocyte differentiation programs (Figure 5D–E and Supplementary file 2f). These effects were
specific because in contrast to CRYBMIM, CREBMIM treatment exhibited minimal changes in gene
expression (Figure 5—figure supplement 1C), consistent with its inability to disrupt the cellular
CBP/P300 complex (Figure 3B). For example, CRYBMIM induced significant increases in the AP-1
family transcription factors FOS and JUN, as well as IL6 and CSF1 that control myeloid differentiation
(Figure 5B; Gonda et al., 1993; Selvakumaran et al., 1992). Nearly 40% of the genes induced by
Figure 4 continued
cells expressing sgCBP-1 and sgCBP-2, as compared to control sgNEG1 and sgNEG2 targeting the AAVS1 safe harbor locus. EP300 is shown for
specificity, and Actin serves as the loading control. (C) Relative growth of GFP-expressing MOLM13 cells expressing mCherry and unique sgRNAs
targeting AAVS1 control (sgNEG1 and sgNEG2), CBP (sgCBP-1 and sgCBP-2), and P300 (sgEP300-1 and sgEP300-2) and quantified by FACS on day 0,
3, and 6 after 2-day treatment with 10 mM CRYBMIM or PBS. Data represent biological triplicates of at least 10,000 cells per condition; *p=6.0e-10,
**p=4.1e-8, t-test for day 6 versus day 0 of CRYBMIM treatment of CBP-depleted cells. (D) Analogous experiment as (C) using MV411 cells; *p=1.1e-6,
**p=3.7e-6, t-test for day 6 versus day 0 of CRYBMIM treatment of CBP-depleted cells.
The online version of this article includes the following figure supplement(s) for figure 4:
Figure supplement 1. Genetic dependencies of CRYBMIM susceptibility in AML cells.
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Figure 5. CRYBMIM blocks oncogenic MYB gene expression and restores normal myeloid cell differentiation. (A–B) Volcano plots of normalized gene
expression of MV411 cells upon one (A) and four hour (B) treatment with CRYBMIM, as compared to PBS control, with select genes labeled; p-values
denote statistical significance of three biological replicates. (C–E) Gene set enrichment analysis of up- and downregulated gene sets: (C) MYB_Q6, (D)
GSE9988_LPS_VS_VEHICLE_TREATED_MONOCYTES_UP, and (E) GERY_CEBP_TARGETS_377. (F) Histogram of Annexin V- or CD11b-stained MV411
Figure 5 continued on next page
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deletion of RUVBL2 were also found to be induced by CRYBMIM treatment, including JUN, FOS,
and FOSB (Armenteros-Monterroso et al., 2019). In agreement with these findings, CRYBMIM
treatment induced significant phenotypic differentiation of MV411 cells, as evidenced by the induc-
tion of monocytic CD11b expression, as measured by flow cytometry (Figure 5F–G). While MYBMIM
primarily induces apoptosis of MV411 cells, CRYBMIM effects include both apoptosis and differentia-
tion, as evident from flow cytometry analyses (Figure 5G). This suggests that differentiation block-
ade is directly linked to oncogenic MYB-dependent gene expression in AML.
Sequestration of CBP/P300 contributes to MYB-dependent
leukemogenic gene expression
The direct link between leukemogenic gene expression and differentiation blockade suggests that
CRYBMIM not only blocks the assembly of the MYB:CBP/P300 complex, but also induces its remod-
eling to promote AML differentiation. To test this hypothesis, we analyzed the occupancy of MYB
and CBP/P300 genome-wide using chromatin immunoprecipitation followed by sequencing (ChIP-
seq). Consistently, we found that CRYBMIM treatment leads to significant redistribution of both
MYB and CBP/P300 on chromatin (Figure 6A–D). For example, after 1 hr of CRYBMIM treatment,
both MYB and CBP/P300 are evicted from loci enriched in the MYB-associated DNA-binding motifs
(Figure 6A and C, lost peaks). By 4 hours of CRYBMIM treatment, MYB was significantly depleted
from 2587 promoters and enhancers, primarily at sites associated with the MYB DNA-binding motifs,
as well as motifs corresponding to NFY, ETS family, AP-1 family, SP1, and C/EBP family member
transcription factors (Figure 6B and D). Noticeably, CBP/P300 was not only depleted from 7579
genes, but also significantly redistributed to 11,324 new loci (Figure 6D), consistent with the remod-
eling of its complex upon CRYBMIM treatment. Loci depleted of CBP/P300 were significantly
enriched in MYB-associated DNA-binding motifs, as well as those corresponding to the SPI1/ETS,
MAF, C/EBP family member, and SP2 transcription factors (Figure 6D). Likewise, loci that gained
CBP/P300 upon CRYBMIM treatment were enriched in DNA-binding motifs for the AP-1, RUNX1,
EGR, and C/EBP family member transcription factors (Figure 6D). In all, peptidomimetic blockade of
MYB:CBP/P300 assembly causes remodeling of transcription factor complexes at loci controlling leu-
kemic gene expression, associated with genome-wide redistribution of CBP/P300 transcriptional co-
activation complexes. Thus, sequestration of CBP/P300 from genes controlling hematopoietic differ-
entiation contributes to the leukemogenic MYB-dependent gene expression.
MYB assembles aberrant transcription factor complexes in AML cells
Dynamic redistribution of CBP/P300 transcription factor complexes associated with distinct transcrip-
tion factor activities upon blockade of MYB:CBP/P300 binding suggests that MYB organizes an aber-
rant transcriptional co-activator complex in AML cells. To define this complex, we used specific
antibodies to immunoprecipitate MYB from non-denatured nuclear extracts of MV411 AML cells,
and identify co-purifying proteins using high-accuracy quantitative mass spectrometry. To control for
abundant proteins and other contaminants that may co-purify non-specifically, we used non-specific
isotype control antibodies and precursor ion quantitation to establish stringent statistical parameters
that led to the identification of 724 unique proteins that are specifically associated with MYB in
MV411 AML cells (Figure 7A). This included CBP itself, as confirmed by the high-confidence identifi-
cation of unique peptide spectra that distinguish CBP from P300, with four additional peptides
shared by both CBP and P300 (Figure 7—figure supplement 1), as well as other known MYB inter-
actors such as CEBPB (Supplementary file 3a).
Figure 5 continued
cell fluorescence, treated with CRYBMIM (red), MYBMIM (gray), or control PBS (black); *p<1e-15, Kruskal-Wallis test. (G) Scatter plots comparing
Annexin V- versus CD11b-stained MV411 cell fluorescence, treated with control PBS, MYBMIM or CRYBMIM; blue to red color indicates increasing cell
density.
The online version of this article includes the following source data and figure supplement(s) for figure 5:
Source data 1. Differential gene expression analysis by RNA-seq in CRYBMIM, CREBMIM vs PBS treated MV411 cells (1 hr and 4 hr).
Figure supplement 1. CRYBMIM but not CREBMIM causes significant changes in gene expression in AML cells upon short duration exposure.
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Figure 6. CRYBMIM remodels MYB and CBP/P300 chromatin complexes in AML cells. (A–B) Volcano plots of relative MYB chromatin occupancy in
MV411 cells changes after 1 hr (A) and 4 hr (B) of 20 mM CRYBMIM treatment compared to PBS control, as analyzed by ChIP-seq. Sequence motifs
found in CRYBMIM-induced MYB-depleted (left) and MYB-enriched loci (right) are shown. p-Values denote statistical significance of three technical
replicates. (C–D) Volcano plots of CBP/P300 chromatin occupancy changes after 1 hr (C) and 4 hr (D) of 20 mM CRYBMIM treatment as compared to
Figure 6 continued on next page
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Because MYB is required for the growth and survival of diverse AML subtypes, we reasoned that
its essential non-redundant co-factors can be identified from the analysis of their functional depen-
dencies, as assessed by genetic CRISPR interference (Tsherniak et al., 2017). We assigned the
CRISPR dependency score of CBP itself in MV411 cells as the threshold to identify functionally non-
redundant MYB:CBP co-factors (Figure 7B). We found that these genes encode factors with diverse
molecular functions, including a group of 59 chromatin-associated proteins (Supplementary file 3b).
By using currently annotated protein-protein interactions (Oughtred et al., 2019), we constructed
their interaction network, based on interactions detected by affinity purifications coupled with either
western immunoblotting or mass spectrometry (Figure 7C). Analysis of their expression in normal
human hematopoietic progenitor as compared to AML cells (Cancer Genome Atlas Research Net-
work et al., 2013), led to the identification of candidate co-factors with apparently aberrant expres-
sion in AML cells (Figure 7C, dark red). Indeed, 10 such factors were selectively required for 37
leukemia but not 615 other non-hematopoietic cancer cells lines (Figure 7D). The physical associa-
tion of MYB, CBFB, ZEB2, C/EBP family members, LYL1, SPI1, RUNX1, LMO2, and GFI1 and their
non-redundant functional dependencies in AML cells (Figure 7A–D) are in agreement with the chro-
matin dynamics involving distinct MYB, C/EBP family members, LYL1, SPI1, and RUNX1 DNA-bind-
ing motifs observed in CRYBMIM-treated cells (Figure 6A–B), associated with the apparent
redistribution and remodeling of their CBP/P300 co-activator complexes (Figure 6C–D). Indeed,
these factors directly associate with the MYB regulatory complex, and their DNA-binding motifs are
enriched at loci affected by CRYBMIM treatment (Figure 6).
To define the composition of the MYB transcription factor complex across biologically and geneti-
cally distinct subtypes of AML, we used co-immunoprecipitation to measure the physical association
of MYB and its cofactors in a panel of AML cell lines, spanning representative cell types with rela-
tively high (MV411, HL60, OCIAML2, OCIAML3) and low (U937, Kasumi-1, K562) susceptibility to
CRYBMIM (Figure 8). We found that in all seven cell lines tested, MYB was physically associated
with LYL1 and E2A transcription factors (Figure 8A). In contrast, LMO2 was physically associated
with MYB in all cell lines except OCIAML2, CEBPA was co-assembled with MYB in OCIAML2 and
U937 cells, and SATB1 was co-assembled with MYB in MV411 and HL60 cells (Figure 8A). These
findings are all in complete agreement with the chromatin dynamics of MYB, as observed using
ChIP-seq (Figure 6). In addition, we corroborated these findings by examining the association of
specific transcription factors with CBP/P300 (Figure 8B). The only exception is SPI1/PU.1, which
does not appear to be physically associated with MYB or CBP/P300 in examined cell lines, suggest-
ing that the apparent SPI1/PU.1 sequence motifs observed in MYB-associated loci are due to other
ETS family factors (Figure 6). In all, MYB assembles a convergently organized transcription factor
complex in genetically diverse AML cells.
MYB transcription complexes are associated with aberrant cofactor
expression and assembly in AML cells
Insofar as various forms of AML exhibit blockade of normal hematopoietic differentiation induced by
distinct leukemia oncogenes, and at least some of the MYB-assembled cofactors have reduced gene
expression in normal CD34+ hematopoietic progenitor cells (Figure 7C), we reasoned that their
assembly in leukemia cells may be due to their aberrant co-expression. To test this, we measured
their protein expression in human AML cells using quantitative fluorescent immunoblotting, as com-
pared to normal human CD34+ umbilical cord blood progenitor, adult peripheral blood B- and
T-lymphocytes, and monocytes (Figure 9A). We found that most transcription factors that are
assembled with MYB in diverse AML cell lines could be detected in one or more normal human
Figure 6 continued
control, as analyzed by ChIP-seq. Sequence motifs found in CRYBMIM-induced CBP/P300-depleted (left) and CBP/P300-enriched loci (right) are shown.
p-Values denote statistical significance of three technical replicates.
The online version of this article includes the following source data and figure supplement(s) for figure 6:
Source data 1. Differentially occupied chromatin loci measured by MYB and CBP/P300 ChIP-seq in CRYBMIM vs PBS treated MV411 cells (1 hr and 4 hr).
Figure supplement 1. CRYBMIM remodels MYB chromatin occupancies in AML cells.
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Figure 7. MYB assembles aberrant nuclear transcription factor complexes in AML cells. (A) Volcano plot of nuclear MYB-associated proteins compared
to IgG control, as analyzed by affinity purification-mass spectrometry of MV411 cells. Red symbols denote specifically MYB-associated proteins, as
defined by association with CBP (MYB/IgG log2 >1). p-Values denote statistical significance of three biological replicates. (B) Enrichment of MYB-
associated proteins (red) as a function of their corresponding CRISPR DepMap dependency scores in MV411 cells. Red symbols denote functionally
Figure 7 continued on next page
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blood cells, albeit with variable abundance, with the exception of CEBPA and SATB1 that were
measurably expressed exclusively in AML cells (Figure 9A).
To determine whether specific combinations of MYB-assembled transcription factors are associ-
ated with the leukemic activity of the MYB complex, we clustered the protein abundance values of
distinct groups of transcription factors using principal component analysis (Figure 9B–D). We found
that this approach exhibited excellent separation between CRYBMIM-sensitive (MV411, OCIAML2,
OCIAML3, HL60) and less sensitive (Kasumi1, K562) cell lines, with the first (PC1, 62%) and second
(PC2, 19%) eigenvectors explaining more than 80% of the variability in CRYBMIM susceptibility
(Figure 9B). In particular, the protein abundance levels of CEBPA and LYL1 exhibited the greatest
contribution to the observed clustering (Figure 9C), consistent with their observed activity in MYB-
assembled chromatin dynamics (Figure 6).
In addition to aberrant co-expression of various MYB-assembled cofactors, their aberrant assem-
bly in leukemia cells may also contribute to their oncogenic functions. To test this hypothesis, we
purified MYB complexes from normal human cord blood progenitor cells using immunoprecipitation,
and determined the abundance of specific cofactors as compared to human AML cells using western
immunoblotting (Figure 9E). While MYB, CBP/P300 and LYL1 were physically associated in normal
umbilical cord blood mononuclear cells, we did not observe their physical association with E2A,
SATB1 and LMO2. In contrast, MYB and CBP/P300 complexes were highly enriched in LYL1, SATB1,
E2A, and LMO2 in MV411 and HL60 AML cells (Figure 9E). Thus, oncogenic MYB transcription fac-
tor complexes are aberrantly organized in AML cells, associated at least in part with inappropriate
transcription factor expression.
If convergent assembly of MYB with common transcription factors in biologically diverse subtypes
of AML is responsible for the induction of oncogenic gene expression and blockade of normal
hematopoietic differentiation, then pharmacologic blockade of this process would suppress shared
gene expression programs associated with AML growth and survival, and promote gene expression
programs associated with hematopoietic differentiation. To test this prediction, we carried out com-
parative gene expression analyses using RNA-sequencing of CRYBMIM effects in AML1-ETO-translo-
cated Kasumi1, DNMTA3A;NPM1-mutant OCIAML3, MLL-rearranged MV411, NRAS-mutant;MYC-
amplified HL60, and CALM10-rearranged U937 AML cell lines (Figure 5A–B and Figure 9—figure
supplement 1). Unsupervised clustering of differentially expressed genes exhibited excellent separa-
tion between CRYBMIM- and PBS-treated cells. In agreement with the prediction, we observed a
shared set of genes that was suppressed in expression upon CRYBMIM treatment of all AML cell
lines, such as MYC for example (Figure 5A and Figure 9—figure supplement 1A–B). Similarly, we
observed a shared set of genes that was induced by CRYBMIM treatment, including numerous genes
associated with hematopoietic differentiation such as FOS, JUN, and ATF3, as well as SERPINE,
KLF6, DDIT3, and NFKBIZ (Figure 5A–B and Figure 9—figure supplement 1B). Thus, oncogenic
gene expression in biologically diverse subtypes of AML involves convergent and aberrant assembly
of MYB transcription factor complexes that induce genes that promote leukemogenesis and repress
genes that control cellular differentiation.
Aberrant organization of the MYB transcription factor complex is
regulated by proteolysis
We noted that MYB:CBP/P300 binding in AML cells was reduced by several orders of magnitude
upon CRYBMIM treatment (Figure 6). This contrasts to the nearly equal binding affinities of
Figure 7 continued
required proteins, as defined by the genetic dependency of CBP (score < 0.18). (C) Network of BioGRID protein interactions for MYB-associated
nuclear AML proteins as a function of their respective hematopoietic expression aberrancy scores, based on their relative gene expression in AML cells
as compared to normal bone human bone marrow progenitor cells (white to red color gradient indicates increasingly aberrant gene expression). (D)
Comparison of the genetic dependency scores in leukemia cell lines as compared to all other non-hematopoietic cancer cell lines for MYB-associated
nuclear AML proteins, with red symbols denoting proteins that are required in leukemia as compared to non-hematopoietic cancers.
The online version of this article includes the following source data and figure supplement(s) for figure 7:
Source data 1. Lists of proteins identified by IP-MS of IgG control and MYB or CBP/P300 complex purifications from MV411 cell nuclei.
Figure supplement 1. CBP is the primary binding partner of MYB in AML cells.
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Figure 8. MYB and CBP/P300 assemble convergently organized nuclear transcription factor complexes in genetically diverse AML cells. (A–B) Western
blots of specific transcription factors in immunoprecipitated MYB (A) and CBP/P300 (B) nuclear complexes in seven genetically diverse AML cell lines, as
indicated. Blue and red bands indicate molecular weight markers. LaminB1 serves as the loading control.
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Figure 9. Specific MYB complex factors are aberrantly expressed and assembled in AML as compared to normal human blood cells. (A) Western blots
of specific MYB complex transcription factors in normal human blood cells and genetically diverse leukemia cells, as indicated. Actin serves as the
loading control. (B) Principal component analysis of MYB complex transcription factor abundance, as quantified by image densitometry, as a function of
susceptibility of various AML cell lines to CRYBMIM (blue color index). (C) Contribution of individual MYB complex transcription factor abundance to the
Figure 9 continued on next page
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CRYBMIM and native MYB to CBP/P300 KIX domain (Figure 2D), suggesting that cellular processes
must contribute to the biologic effects of CRYBMIM. Thus, we examined cellular MYB protein levels
using quantitative immunoblotting (Figure 10A, Figure 10—figure supplement 1). We found that
CRYBMIM treatment induced nearly 10-fold reductions in cellular MYB protein levels with exponen-
tial kinetics on the time-scale of 1–4 hr in CRYBMIM-sensitive MV411, HL60, OCIAML2, and
OCIAML3 cells. In contrast, CRYBMIM treatment induced less pronounced depletion of MYB in
U937, Kasumi1, and K562 cells that are less sensitive to CRYBMIM. Susceptibility of diverse AML cell
lines to CRYBMIM, as measured by cell viability (Figure 3G), was significantly correlated with the
apparent kinetics of MYB protein decay (Pearson r = 0.94; Figure 10B).
Rapid reduction of MYB protein levels by CRYBMIM is consistent with proteolysis. To investigate
this directly, we quantified CRYBMIM-induced reduction of MYB protein levels in MV411 cells upon
co-treatment with the proteosomal/protease inhibitor MG132 (Figure 10C). Consistent with the pro-
teolytic depletion of MYB upon CRYBMIM treatment, MG132 co-treatment led to near complete
rescue of this effect (Figure 10C). This effect was specific because overexpression of BCL2, which
blocks MYBMIM-induced apoptosis (Ramaswamy et al., 2018), and rescued the depletion of cellular
CREB, presumably due to non-specific proteolysis that accompanies apoptosis, was unable to rescue
CRYBMIM-induced proteolysis of MYB (Figure 10C). Since CBP is required for the anti-leukemic
effects of CRYBMIM, we queried whether MYB protein levels are affected by CBP depletion. We
observed no measurable differences in MYB protein levels between wild-type, CBP-deficient or con-
trol AAVS1-CRISPR targeted MV-411 cells (Figure 10—figure supplement 1C). This suggests that
either P300 can compensate for CBP-mediated functions, and/or MYB proteolysis is not regulated
solely by its interaction with CBP/P300, but requires specific activities of CBP/P300 induced by
CRYBMIM. In all, MYB transcription complexes are regulated by specific factor proteolysis in AML
cells and can be induced by its peptidomimetic blockade.
Release and redistribution of MYB-sequestered transcription factors
restores normal myeloid differentiation
We reasoned that the remodeling of MYB regulatory complexes and their associated chromatin fac-
tors such as CBP/P300 are responsible for the anti-leukemia effects of CRYBMIM, at least in part via
reactivation of cellular differentiation of MV411 AML cells (Figure 5). To test this, we prioritized
CEBPA, LYL1, SPI1, and RUNX1 as MYB-associated co-factors based on their physical interactions
and functional dependencies in AML cells (Figure 7), and analyzed their chromatin dynamics in
response to CRYBMIM treatment using ChIP-seq analysis. Consistent with the release and redistribu-
tion mechanism, we observed both coherent and factor-specific dynamics of MYB co-factors on
chromatin upon CRYBMIM treatment (Figure 11A). Clustering of observed dynamics revealed nine
classes of apparent chromatin responses (Figure 11B). Approximately one-third of the affected
genes lost both MYB and CBP/P300 in response to CRYBMIM, as well as RUNX1, LYL1, and/or
CEBPA (Figure 11B; yellow clusters 1, 3, and 6). Genes in the MYB and CBP/P300-depleted clusters
1, 3, and 6 were enriched in those associated with the development of hematopoietic progenitor
cells, as well as MYC and HOXA9/MEIS1 targets (Supplementary file 3c), consistent with current
and past gene expression profiling studies (Figure 5 and Figure 9—figure supplement 1). In addi-
tion, these genes were enriched in pathways involving chromatin repression, consistent with the
enrichment of DNA-binding sequence motifs of transcriptional repressors YY1 and REST/NRSF
(Figure 11B). This suggests a potential mechanism for the long-hypothesized repressive functions of
MYB. While we found no apparent changes in JUN occupancy, motif analysis at loci that both lost
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top PCA eigenvector. (D) Heatmap of hierarchical clustering of MYB complex individual transcription factor abundance and CRYBMIM susceptibility. (E)
Western blots of specific transcription factors in specific MYB nuclear complexes immunoprecipitated from normal human umbilical cord mononuclear
cells (MNC), as compared to MV411 and HL60 AML cells. Blue and red bands indicate molecular weight markers. LaminB1 serves as loading control.
The online version of this article includes the following source data and figure supplement(s) for figure 9:
Source data 1. All coding gene expression changes measured by RNA-seq in 1 hr CRYBMIM vs PBS treated 5 AML cell lines.
Figure supplement 1. MYB transcription complexes induce shared and repress distinct gene expression programs in genetically diverse AML cells, as
remodeled by peptidomimetic CRYBMIM inhibition.
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Figure 10. Peptidomimetic remodeling of MYB transcriptional complexes leads to rapid MYB proteolysis. (A) Quantification of MYB abundance in HL60
cells as a function of duration of 20 mM CRYBMIM treatment (red) as compared to PBS control (black) using Western blot image densitometry. Lines
represent single exponential decay fits. Western blots and fits for all cell lines studied are shown in Figure 10—figure supplement 1. Symbols
represent biological triplicates. (B) MYB protein half-life, as estimated by exponential decay kinetics, in genetically diverse AML cell lines as a function
of CRYBMIM susceptibility (Pearson r = 0.94, excluding resistant K562). Horizontal bars represent standard deviation of CRYBMIM susceptibility. Vertical
bars represent standard deviation of time constants. (C) Western blots of MYB and CREB in MV411 AML cells transduced with MSCV retroviruses
encoding GFP control (MV411-MSCV) or BCL2 (MV411-BCL2), treated with 20 mM CRYBMIM or PBS control with or without 10 mM of MG132 for 1 or 4
hr, as indicated. Actin serves as loading control.
The online version of this article includes the following figure supplement(s) for figure 10:
Figure 10 continued on next page
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and gained MYB and CBP/P300 revealed enrichment of AP-1 sequence elements, consistent with
the presence of other AP-1 family member(s) in MYB regulatory complexes. Minor apparent contri-
bution of MYB:CBP/P300-independent chromatin dynamics involved genes enriched in MLL targets
(Figure 11B, Supplementary file 3c; blue clusters 5, 8), consistent with the activity of MLL fusion
proteins in MV411 cells.
Notably, the two chromatin dynamics clusters 4 and 9 that gained both MYB and CBP/P300 in
response to CRYBMIM, associated with the accumulation of CEBPA, RUNX1, and/or CREB, were
enriched in genes controlling myeloid differentiation programs (Figure 11B; orange, and
Supplementary file 3c). This is consistent with the CRYBMIM-induced gene expression differentia-
tion programs and accompanying morphologic features of myeloid differentiation (Figure 5). While
CRYBMIM induces MYB proteolysis, residual MYB can remain bound to chromatin, as evident by its
accumulation in specific loci upon CRYBMIM treatment. MYB-binding loci lost upon CRYBMIM treat-
ment showed significant enrichment for known MYB binding motifs, while CRYBMIM-induced MYB
peaks did not (p=1e-149 vs 1e-3, 56% vs 5.7% of target sites, respectively). This raises the possibility
that DNA-binding affinity of MYB could be regulated by CBP/P300, either by direct effects such as
MYB deacetylation upon CRYBMIM treatment, or indirectly via binding with other transcription fac-
tors. It is possible that other transcription factors may contribute to oncogenic gene expression in
AML cells, such as CREB for example, as evident from their contribution to MYB-independent chro-
matin dynamics (Figure 11B; pink cluster 2). However, this is likely a minor effect, given the relatively
modest reprogramming of gene expression by CREBMIM that targets the CREB:CBP/P300 com-
plexes in AML cells (Figure 5 and Figure 5—figure supplement 1).
Globally, the most pronounced feature of MYB complex remodeling is the release of CBP/P300
from genes that are associated with AML cell growth and survival to those that are associated with
hematopoietic differentiation. To examine this, we compared relative gene expression as a function
of the relative occupancy of CBP/P300 and MYB upon 4 hr of CRYBMIM treatment (Figure 11—fig-
ure supplement 1A–B). In contrast to the model in which blockade of MYB:CBP/P300 induces loss
of gene expression and loss of transcription factor and CBP/P300 chromatin occupancy, we also
observed a large number of genes with increased expression and gain of CBP/P300 occupancy (Fig-
ure 11—figure supplement 1A–B). This includes numerous genes that control hematopoietic differ-
entiation, such as FOS, JUN, and ATF3. In the case of FOS, we observed that CRYBMIM-induced
accumulation of CBP/P300 was associated with increased binding of RUNX1, and eviction of CEBPA
and LYL1 (Figure 11—figure supplement 1C).
To confirm directly that peptidomimetic blockade of MYB:CBP/P300 releases CBP/P300 and pro-
motes its association with alternative transcription factors, we specifically immunoprecipitated MYB
and CBP/P300 from MV411 AML cells using respective antibodies, and determined their composi-
tion by western immunoblotting (Figure 12A–B). In agreement with biochemical studies, we
observed substantial depletion of CBP/P300 from immunoprecipitated MYB complexes upon CRYB-
MIM treatment (Figure 12A), and of MYB from immunoprecipitated CBP/300 complexes
(Figure 12B). Similarly, we observed reduced binding of LYL1, SATB1, E2A, LMO2, and CEBPA. In
contrast, whereas no detectable RUNX1 was found co-associated with MYB either at baseline or
upon CRYBMIM treatment (Figure 12A), assembly of RUNX1 with CBP/P300 was increased by more
than fourfold upon CRYBMIM treatment, as measured by image densitometry (p=3.4e-4;
Figure 12B–C).
In all, these results support the model in which the core regulatory circuitry of AML cells is orga-
nized aberrantly by MYB and its associated co-factors including LYL1, C/EBP family members, E2A,
SATB1 and LMO2, which co-operate in the induction and maintenance of oncogenic gene expres-
sion, as presumably co-opted by distinct oncogenes in biologically diverse subtypes of AML (Fig-
ure 13). This involves apparent sequestration of CBP/P300 from genes controlling myeloid cell
differentiation. Thus, oncogenic gene expression is associated with the assembly of aberrantly orga-
nized MYB transcriptional co-activator complexes, and their dynamic remodeling by selective
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Figure supplement 1. CRYBMIM causes MYB proteolysis with differential degradation rates in AML cells.
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Figure 11. Chromatin dynamics of CRYBMIM remodeled MYB transcription factor complexes in AML cells. (A) Heatmap of transcription factor
chromatin occupancy in MV411 cells as a function of time of control PBS or CRYBMIM treatment. Nine clusters identified using k-means clustering are
marked by yellow (loss of MYB and CBP), purple (loss of CBP and gain of MYB), orange (gain of MYB and CBP), pink (gain of CBP), and blue (no
apparent changes of MYB and CBP) boxes, based on the similarity of their z-scores, with red and blue representing enrichment or depletion of factors,
Figure 11 continued on next page
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blockade of protein interactions can be leveraged therapeutically to induce AML cell differentiation
and apoptosis.
Discussion
Dysregulated gene expression is a near universal feature of all human cancers. This is particularly rel-
evant for leukemias which are frequently caused by mutations of genes encoding transcription and
chromatin remodeling factors. Among all types of leukemias examined to date, the transcription fac-
tor MYB ranks as the most selectively required functional genetic dependency. This nominates MYB
both as a compelling therapeutic target, and a focus of mechanistic studies to define fundamental
mechanisms of dysregulated gene expression in leukemias.
By rapid and selective peptidomimetic interference with the binding of CBP/P300 to MYB, but
not CREB or MLL, we find that the leukemic functions of MYB are mediated by CBP/P300-mediated
co-activation of a distinct set of transcriptional factor complexes that are aberrantly assembled with
MYB in AML cells. The second-generation, cell-penetrant peptidomimetic MYB inhibitor, termed
CRYBMIM, has potent and broad-spectrum activity against diverse subtypes of AML, while relatively
sparing normal hematopoietic progenitor cells. Consequently, its improved activity enables high-res-
olution, genome-wide studies of chromatin and gene expression dynamics that control MYB-depen-
dent leukemic expression in AML cells. We find that CRYBMIM blocks oncogenic MYB gene
expression and restores myeloid cell differentiation. This effect involves aberrantly organized MYB
regulatory complexes, stably composed of additional transcription factors including LYL1, C/EBP
family members, E2A, LMO2 and SATB1, that are reminiscent of core regulatory circuits observed in
MYB-dependent T-cell lymphoblastic leukemias and other cancers (Mansour et al., 2014;
Sanda et al., 2012). Unexpectedly, we find that MYB-dependent leukemogenic gene expression
also involves apparent sequestration of CBP/P300. In turn, peptidomimetic MYB:CBP/P300 blockade
releases and redistributes CBP/P300 and other sequestered transcription factors to induce cell dif-
ferentiation. In all, these findings establish a compelling strategy for pharmacologic reprogramming
of oncogenic gene expression that supports its targeting for leukemias and other human cancers
caused by dysregulated gene control.
What is the origin of aberrant MYB transcriptional complexes and functions in leukemia cells?
MYB is not known to be mutated in most cases of AML, and this study points to its aberrant assem-
bly as the convergent mechanism by which it is pathogenically dysregulated. Indeed, previous stud-
ies have found cell-type-specific features of MYB gene activation, suggesting the presence of other
factors that influence MYB activity (Lei et al., 2004). Furthermore, MYB alone is not sufficient for leu-
kemic cell transformation, indicating the need for specific co-factors in its leukemogenic activity
(Gonda et al., 1989; Hu et al., 1991).
By integrating functional genomics and proteomics, combined with gene expression and chroma-
tin dynamics analyses, we identified a set of factors in complex with MYB that appear to be aber-
rantly and stably co-assembled, including C/EBP family members, LYL1, E2A, LMO2, and SATB1.
Their physical interactions and chromatin co-localization with MYB are associated with oncogenic
gene expression and blockade of cell differentiation in AML cells. Interestingly, we found no CRYB-
MIM-induced remodeling of MYB regulatory complexes independent of CBP/P300, indicating that
KIX-dependent interaction between MYB and CBP/P300 is required for most of MYB transcriptional
activity in AML cells.
It is possible that somatic mutations of regulatory DNA elements, such as those physically associ-
ated with MYB regulatory complexes, contribute to the aberrant assembly of these complexes on
chromatin, as observed for the oncogenic TAL1 enhancer mutations in cases of T-ALL
Figure 11 continued
respectively. (B) Groups of clusters comprising similar responses to CRYBMIM treatment based on MYB and CBP/P300 dynamics. Sequence motifs
enriched at specific loci for each cluster are listed. Factors in white denote factors presumed to be enriched based on sequence motif enrichment.
The online version of this article includes the following source data and figure supplement(s) for figure 11:
Source data 1. Differentially increased or decreased peaks measured by multiple TF ChIP-seq in 1 hr CRYBMIM vs PBS-treated MV411 cells.
Figure supplement 1. Oncogenic MYB transcription complexes sequester CBP/P300 to control AML gene expression.
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Figure 12. Peptidomimetic blockade of MYB:CBP/P300 by CRYBMIM releases CBP/P300 that recruits RUNX1 to chromatin. (A–B) Western blots of
specific transcription factors in nuclear complexes with immunoprecipitated MYB (A) and CBP/P300 (B) in MV411 cells upon treatment with 10 mM
CRYBMIM or PBS control for 1 hr. Blue and red bands indicate molecular weight markers. LaminB1 serves as loading control. (C) Abundance of MYB,
CBP/P300 and RUNX1, as measured by western blot image densitometry, in immunoprecipitated MYB and CBP/300 nuclear complexes in MV411 cells
Figure 12 continued on next page
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(Mansour et al., 2014), and recently suggested for other leukemias (He et al., 2019). It is also possi-
ble that leukemic gene expression by MYB involves additional transcriptional co-activators, such as
TAF12, as part of the recently described TFIID-SAGA complex interaction (Xu et al., 2018), or other
TAFs which have also been implicated in transcriptional co-regulation in leukemias (Jian et al., 2017;
Xu et al., 2019). Lastly, it is also possible that distinct subtypes of AML diverge from the aberrant
regulatory complex assembly model presented here. For example, LYL1, an oncogene that is aber-
rantly expressed in diverse subtypes of AML (Meng et al., 2005), assembles with MYB in leukemia
cells examined in our study, similar to its functional homologue TAL1 in cases of T-ALL
(Mansour et al., 2014; Sanda et al., 2012). Alternative bHLH transcription factors may cooperate
with MYB in some leukemia subtypes, including potential differences in their cells of origin
(Jones, 2004). It will be important to determine how aberrant co-expression of such oncogenic regu-
latory complex co-factors is induced in leukemia cells by diverse oncogenes, such as for example by
kinase-dependent dysregulation of transcription factor assembly recently described for MEF2C and
LYL1 (Brown et al., 2018; Tarumoto et al., 2018; Vakoc and Kentsis, 2018).
The switch-like response of AML cells to peptidomimetic disassembly of the MYB:CBP/P300 chro-
matin complex suggests that cellular CBP/P300 exists in a dynamic equilibrium under limiting condi-
tions. Such a model is supported by the Rubinstein-Taybi syndrome due to heterozygous deletion
mutations that reduce CBP gene dosage, leading to human developmental defects. This model also
explains the distinct requirements of CBP and P300 in normal hematopoiesis and leukemia cell
development (Cheng et al., 2017; Wang et al., 2011), as also observed in our studies in genetically
diverse AML cell types, as well as the functional requirement for P300 in CBP-deficient cancers
(Ogiwara et al., 2016). Definition of the mechanisms of this molecular switch regulating discrete
gene expression programs is expected to reveal distinct mechanisms of dysregulated gene control
in AML and other transcription-dysregulated cancers.
Current small molecule inhibitors of MYB lack sufficient selectivity (Pattabiraman and Gonda,
2013; Uttarkar et al., 2015; Uttarkar et al., 2016). Our peptidomimetic strategy suggests that
structure-based design of effective pharmacologic MYB inhibitors is not only possible, but also desir-
able given its favorable therapeutic index. First, the functional requirement for peptidomimetic
blockade of MYB but not CREB or MLL1 binding in supporting oncogenic gene expression and cell
survival suggests that ligands to these permissive binding sites may be used to gain binding affinity
of pharmacologic MYB inhibitors. Indeed, such a fragment-based design strategy was successfully
used to develop effective BH3 mimetics, including venetoclax that has recently been approved for
leukemia therapy.
Quantitative improvement in binding affinity from MYBMIM to CRYBMIM is associated with quali-
tative improvement in biological potency, due to the combination of enhanced MYB:CBP/P300 bind-
ing competition and proteolytic remodeling of its complex. Such event-driven pharmacology has
recently been used to develop a variety of pharmacologic modulators of protein interactions, such
as PROTACs. The dual mechanism of action observed for peptidomimetic MYB:CBP/P300 inhibitors,
involving suppression of oncogenic MYB activity and remodeling of CBP/P300, provides a pharma-
cologic strategy for both precise chemical probes and improved therapeutics. Indeed, ligation of the
KIX domain of CBP/P300 by CRYBMIM may allosterically modulate the activity of its complexes, simi-
lar to the allosteric regulation of its acetyltransferase activity by auto-acetylation and intramolecular
bromodomain binding.
Functional proteomic maps of MYB regulatory complexes provided by our study should be useful
in identifying key protein-protein interactions and post-translational enzymatic modifications that are
aberrantly induced in AML cells, as targets for improved therapies. For example, this may involve
transcription factor acetylation by CBP/P300 (Roe et al., 2015; Wang et al., 2011), warranting the
investigation of recently developed selective CBP/P300 acetyltransferase inhibitors, which have
shown particular activity in hematopoietic cancers (Lasko et al., 2017).
Finally, recent studies have found that stable non-genetic resistance is a common feature of
relapsed AML, and this resistance at least in part is due to the use of alternative enhancers to sustain
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treated with CRYBMIM or PBS control. Symbols represent biological triplicates; *p=4.7e-6, t-test for CBP in MYB complex upon CRYBMIM treatment,
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Figure 13. Convergent organization of aberrant MYB complexes controls oncogenic gene expression in acute myeloid leukemia. Schematic of the
molecular organization of MYB transcription factor complexes, induced convergently in genetically diverse subtypes of AML, leading to oncogenic
gene expression that requires MYB:CBP/P300 interaction and causes susceptibility to its peptidomimetic remodeling, leading to MYB chromatin
eviction and proteolysis, and CBP/P300 release to induce cellular differentiation and apoptosis.
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aberrant gene expression (Bell et al., 2019). Therapeutic remodeling of complexes of master regula-
tors such as MYB may constitute an effective strategy to reprogram oncogenic gene expression that
may prevent or overcome such resistance, providing a platform for therapy of regulatory complex-
mediated gene dysregulation in human cancers. Development and investigation of clinical-grade
MYB inhibitors, including improved derivatives of MYBMIM and CRYBMIM, are important directions
of future work for patients with MYB-dependent acute myeloid and lymphoblastic leukemias, blastic
plasmacytoid dendritic cell neoplasms, gliomas, breast, colon, and adenoid cystic carcinomas.
Materials and methods
Reagents
Synthetic peptides were produced by solid phase synthesis, purified by liquid chromatography, and
confirmed by mass spectrometry (Tufts University Core Facility). Peptides were dissolved in phos-
phate buffered saline (PBS) at a concentration of 1 mM, as measured using optical absorbance meas-
urements at 280 nm. Cell culture media was obtained from Corning. All cell lysis buffers were
supplemented with protease inhibitors comprised of AEBSF (0.5 mM, Santa Cruz, SC-202041B), bes-
tatin (0.01 mM, Fisher/Alfa Aesar, J61106-MD), leupeptin (0.1 mM, Santa Cruz, SC-295358B), and
pepstatin (0.001 mM, Santa Cruz, SC-45036A), and cOmplete, EDTA-free Protease Inhibitor Cocktail
(Roche) as required. MG132 was obtained from Cell Signaling Technologies.
Plasmids
MSCV-IRES-GFP retroviral vector encoding human BCL2 was a gift from Takaomi Sanda
(Sanda et al., 2013; Ramaswamy et al., 2018). Plasmids used for genome-wide CRISPR screen and
CRISPR-competitive assays are described below.
Cell culture
The cell lines MV411, MOLM13, OCIAML2, THP1, NB4, KasumiI1, HEL, OCIAML3, SKM1, U937,
HL60, and K562 were obtained from the American Type Culture Collection (ATCC, Manassas, Vir-
ginia, USA) or DSMZ (Leibniz Institute, Braunschweig, Germany). The identity of all cell lines was veri-
fied by STR analysis (Integrated Genomics Operation Core Facility, MSKCC) and absence of
Mycoplasma contamination was determined using Lonza MycoAlert (Lonza Walkersville, Inc, Wal-
kersville, MD, USA). Cell lines were cultured in 5% CO2 in a humidified atmosphere at 37˚C and were
maintained in RPMI 1640 medium (Corning) supplemented with 10% fetal bovine serum (FBS)
(VWR), antibiotics (100 U/ml penicillin and 100 mg/mL streptomycin), and L-glutamine (1%), referred
to as complete media. Human umbilical cord blood was obtained from the New York Blood Center.
Human B lymphocytes, CD8+ T cells, and monocytes were obtained from Cellero.
Genome-wide CRISPR screen
Cas9-expressing MOLM13 cells were established by transduction with LentiV_Cas9_Blast
(Tarumoto et al., 2020), and then the cells were infected with lentivirus of human CRISPR Knockout
GeCKOv2 library (Sanjana et al., 2014) with MOI of approximately 0.3 for transduction of single
guide RNA per cell. After selection of guide RNA-positive cells by 3 days of puromycin (1 mg/ml)
treatment, the cells were divided into three populations, in which guide RNA representation was
approximately 500 cells/guide. One of the populations was harvested as T0 sample. The other popu-
lations were treated with 10 mM MYBMIM or PBS for 3 days, followed by culture without MYBMIM
or PBS for about a week to allow the survived cells to grow, and harvested as T1 sample. Genomic
DNA was isolated using phenol/chloroform extraction. Illumina sequencing library was generated by
two-step PCR where guide RNA regions were first amplified, followed by the amplification with pri-
mers containing sequencing adaptor/barcodes. Barcoded libraries were pooled and analyzed by sin-
gle-end sequencing using NextSeq 500 (Illumina). MAGeCK tools (Li et al., 2014) were used to
count guide RNA reads in each sample and to calculate log fold-change and p-value between T0
and T1 samples to identify the guide RNAs enriched in T1 population. Screens were performed in
biologic duplicates.
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Molecular modeling
All structures were built using Maestro (Schrodinger). Structures of KIX with MYB, CREB, and MLL
peptides were modeled based on PDB IDs 1SBO, 1KDX, and 2LSX, respectively. For CRYBMIM, PDB
1KDX was used as a starting model, replacing CREB amino acids 137–146 with MYB amino acids
298–310. Resulting models were energy minimized using MacroModel (Schrodinger) using the
OPLS_2005 force field with implicit water at a dielectric constant of 80.
Protein expression and purification
CBP KIX was purified as described previously (Ramaswamy et al., 2018). Briefly, BL21(DE3) cells
(Invitrogen) transformed with pGEX-KIX plasmid were induced at 37˚ C with isopropyl beta-D-1-thio-
galactopyranoside (IPTG) for 3 hr. Cells were harvested by centrifugation at 3000 x g for 15 min. Pel-
lets were resuspended in lysis buffer of 50 mM Tris-HCl pH 7.3, 150 mM NaCl, 0.1% Tween-20, 1
mM DTT, 5 mM EDTA, supplemented with protease inhibitors at a ratio of 50 mL lysis buffer per 1 L
of bacterial culture. Cells were lysed for ten minutes on ice (15 s on, 15 s off, 40% amplitude) using
the Misonix probe sonicator (Qsonica, Newtown, CT). Lysates were cleared by centrifugation for 1 hr
at 21,800 x g at 4˚ C. Cleared lysates were incubated with 4 mL glutathione agarose resin slurry
(GoldBio) for 1 hr at 4˚C to capture GST-KIX. Resin was washed four times with 50 mM Tris-HCl pH
7.4, 150 mM NaCl. KIX domain was cleaved from GST by incubation of resin-bound GST-KIX with
160 U thrombin (GE Healthcare) overnight at room temperature. Resin was centrifuged at 500 x g
for 5 min. Supernatant containing cleaved KIX was collected and dialyzed at 4˚ C against 1 L of 50
mM MOPS pH 6.5, 50 mM NaCl, 10% glycerol, 1 mM tris-2-carboxyethylphosphine (TCEP) overnight
at 4˚C with mixing. Cleaved KIX was purified using a linear gradient of 50 mM to 1 M NaCl over ten
column volumes by cation exchange chromatography using MonoS 5/50 GL column at a flow rate of
1 mL per minute (GE Healthcare). Fractions containing purified KIX were confirmed by SDS-PAGE
and dialyzed against 1 L of 50 mM potassium phosphate pH 5.5, 150 mM NaCl, 10 mM TCEP, 30%
glycerol overnight at 4˚C with mixing. Purified protein was aliquoted and stored at  80˚C.
Microscale thermophoresis
Binding of purified recombinant KIX with fluorescein isothiocyanate (FITC)-conjugated peptides was
measured by microscale thermophoresis using the Monolith NT.115 (NanoTemper Technologies).
Assays were conducted in 50 mM sodium phosphate, 150 mM NaCl, 0.01% NP-40, pH 5.5. FITC-
conjugated peptides (FITC-CREBMIM at 300 nM, FITC-CRYBMIM at 250 nM, and FITC-MYBMIM at
2000 nM, as based on the optical absorbance measurements of FITC at 495 nm) were mixed with
increasing concentrations of purified KIX (0.0015 to 50 mM, 1:1 serial dilutions) and loaded into MST
Premium Coated capillaries. MST measurements were recorded at room temperature for 10 s per
capillary using fixed IR-laser power of 80% and LED excitation power of 40–50%.
Streptavidin affinity chromatography
Streptavidin magnetic beads (Pierce) were washed with 30 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1%
Tween-20 (TBST) twice prior to use. For each purification, 100 mL of streptavidin beads were used (1
mg beads, binding capacity 3500 pmol biotinylated fluorescein per mg). Biotinylated peptides were
bound to streptavidin bead slurry by incubation at room temperature for 1 hr in TBST. Peptide-
bound beads were washed twice in TBST and immediately used for purifications. Nuclear lysates
were extracted as described below for co-immunoprecipitation. Twenty million cells were used per
purification. Nuclear lysates were incubated with Bio-CRYBMIM or Bio-CREBMIM as indicated for 1
hr at room temperature with rotation. Beads were washed twice in lysis buffer and separated for
subsequent competition. Per competition, beads were incubated in a total of 1 mL of lysis buffer
supplemented with competing peptide for 1 hr at room temperature with rotation. Beads were
washed twice in lysis buffer. Bound proteins were eluted by adding 40 mL of western blot sample
buffer described below and incubated for 20 min at 95˚C, with vortexing half-way through.
Sequence analysis
Sequence alignment was performed and identity/similarity of each set of sequences were calculated
by EMBOSS Needle using the Needleman-Wunsch algorithm from EMBL-EBI (https://www.ebi.ac.
uk/Tools/psa/).
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Confocal fluorescence microscopy
Confocal imaging was performed using the Zeiss LSM880 confocal microscope and 63X objective
with 1.5 micron z-stack images. Nunc Lab-tek II 8-chamber coverslips were prepared for cell adhe-
sion by the addition of poly-L-Lysine and incubation at room temperature for 1 hr. Poly-L-lysine solu-
tion was removed from each chamber and chambers were allowed to air dry. A total of 2  105 cells
in 200 mL of fresh media were added to each chamber and incubated for 1 hr at 37˚C for attachment.
FITC-conjugated peptides were added to cell suspensions at a concentration of 100 nM, mixed, and
incubated for 1 hr at 37˚C. Cells were counter-stained using Hoechst 33342 and Mitotracker Red
CMX ROS (MProbes) for 10 min at a final dilution of 1:10,000 prior to imaging.
Colony formation assays
Mononuclear cells were isolated from blood using Ficoll-Paque PLUS density centrifugation and
enriched for CD34+ cells using the CD34 MicroBead Kit UltraPure, according to the manufacturer’s
instructions (MACS Miltenyi Biotech, Bergisch Gladbach, German). Methocult H4034 Optimum
(StemCell Technologies) semi-solid media, which contains recombinant human SCF, GM-CSF,
G-CSF, IL-3, and erythropoietin, was used for the growth of hematopoietic progenitor cells in col-
ony-forming units. CD34+ cells or MV411 cells were resuspended in Iscove’s Modified Dulbecco’s
Medium (IMDM, Corning) media supplemented with 2% FBS at a concentration of 2  105 cells/mL.
The cell suspension, the indicated peptide solution at the appropriate concentration, and Methocult
H4034 were mixed in a ratio of 0.5/0.5/10 (cell suspension/peptide solution/Methocult) for a final
cell concentration of 1000 cells/well of six-well plates. Mixture was vortexed for 30 s and incubated
at room temperature for 5 min. Using a blunt-end 16 G needle (StemCell Technologies), 1.1 mL of
the solution was added to each well of six-well plates. Peptide treatment conditions were analyzed
in biological triplicates. Plates were incubated at 37˚C with 5% CO2 for 14 days. The plates were
imaged using a Zeiss AxioObserver.Z1 (Zeiss, Oberkochen, Germany) with a 10x/0.45NA objective.
Entire well was scanned using transmitted light and the resulting images were stitched using ZEN
Blue 2.3 Desk (Zeiss, Oberkochen, Germany) and then exported at half resolution to tif files.
Cell viability studies
Cells were resuspended in fresh media and plated at a concentration of 2  105 cells in 200 mL per
well in a 96-well plate. Peptides or PBS control were added at indicated concentrations. Cells were
incubated at 37˚C with 5% CO2 for 6 days with media and peptide replacement every 48 hr. On day
6, cell viability was assessed using the CellTiter-Glo Luminescent Viability assay, according to the
manufacturer’s instructions (Promega). Luminescence was recorded using the Infinite M1000Pro
plate reader with an integration time of 250 ms (Tecan). For dose-response assays, cells were resus-
pended and plated at a concentration of 2000 cells in 200 mL per well of a 96-well plate. MV411 cells
were plated in complete RPMI media described above. CD34+ cells isolated from umbilical cord
blood were plated IMDM media supplemented with 15% FBS, 100 U/mL penicillin and 100 mg/mL
streptomycin, 1% L-glutamine, recombinant human cytokines (PeproTech: 100 ng/mL SCF, 100 ng/
mL TPO, 100 ng/mL FLT3, 20 ng/mL IL-6, 20 ng/mL IL-3), and 50 mM b-mercaptoethanol. Increasing
concentrations of peptides (0.78–100 mM; 1:1 serial dilution) were added as indicated. Cells were
incubated for 48 hr at 37˚C with 5% CO2. Cell viability was assessed using Cell Titer Glo as described
above.
CRISPR competitive assays
Cas9-expressing AML cell lines, MOLM13, MV411, OCIAML3, Kasumi1, and K562, were established
by lentiviral transduction with a Cas9 expression vector EFS-Cas9-P2A-Puro, as described (Lu et al.,
2018; Tarumoto et al., 2018). Indicated gene-targeting sgRNAs were cloned into LRG2.1 (U6-
sgRNA-GFP) or LRC2.1 (U6-sgRNA-mCherry), as described (Lu et al., 2018; Tarumoto et al., 2018).
Specific sgRNA sequences are listed in Supplementary file 1c. Lentivirus for each sgRNA was pro-
duced by transfecting HEK293T cells with sgRNA-expression vector and helper plasmids, pMD2.G,
and psPAX2, using TransIT-LT1 Transfection Reagent (Mirus Bio LLC, Madison, WI, USA) according
to the manufacture’s instruction. Virus supernatant was collected at 48 and 72 hr post-transfection,
pooled, filtered, concentrated by centrifugation using the Amicon Ultra-15 Centrifugal Filter Units
(EMD Millipore, Darmstadt, Germany) and stored at  80˚C. Cas9-expressing AML cells were
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transduced with sgRNA virus particles by spin infection (3500 rpm, 35˚C, 90 min) and the subsequent
overnight incubation (37˚C with 5% CO2) in the presence of 8 mg/ml polybrene. Fresh complete
media was supplied to the cells on the next day and every 3 days subsequently. One week after
infection, cells were treated with 10 mM or 20 mM of CRYBMIM or PBS for 2 days. After treatment
completion, live cells were purified using EasySep Dead Cell Removal (Annexin V) Kit (StemCell
Technologies). The remaining viable cells were further incubated in complete media without CRYB-
MIM for 6–9 days with media replacement every 3 days. mCherry- and GFP-expressing cells were
quantified using flow cytometry (BD Fortessa, Becton Dickinson, San Jose, CA).
Western blot analysis
Cells were lysed in 30 mM Tris-HCl pH 6.8, 1% SDS, 2% beta-mercaptoethanol, 7% glycerol,
0.0002% Bromophenol Blue buffer or Laemmli sample buffer (BioRad) supplemented with protease
inhibitors at a ratio of 100 or 200 mL sample buffer per 1 million cells. Cell suspensions were incu-
bated at 95˚C for 15 min, with vortexing every 5 min. Lysates were clarified by centrifugation for 5
min at 18,000 x g. Twenty mL of clarified lysates were resolved by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) using 4–12% or 10% polyacrylamide Bis-Tris gels (Invitrogen)
and transferred onto Immobilon FL PVDF or P PVDF membranes (Millipore, Billerica, MA, USA) at
30V for 30–120 min, for fluorescent or chemiluminescent blotting, respectively. For fluorescent west-
ern blotting, membranes were blocked using Odyssey Blocking buffer (Li-Cor, Lincoln, Nebraska,
USA). Blots were incubated in primary antibodies as indicated. Blotted membranes were visualized
using secondary antibodies conjugated to IRDye 800CW or IRDye 680RD (goat anti-rabbit, 1:15,000,
and goat anti-mouse, 1:15,000) and the Odyssey CLx fluorescence scanner, according to manufac-
turer’s instructions (Li-Cor, Lincoln, Nebraska, USA). After visualization, bands of interest were
selected and signal intensity was quantified using the Image Studio Lite. For some whole cell lysate
analysis and all co-IP experiments, chemiluminescent western blotting was used. Blotted membranes
were blocked using 5% non-fat milk in TBS, incubated in primary antibodies as indicated, and visual-
ized using HRP-conjugated secondary antibodies (donkey anti-rabbit, 1:15,000, and sheep anti-
mouse, 1:15,000, GE Healthcare) and ECL substrate (SuperSignal West Femto Maximum Sensitivity
Substrate and Atto Ultimate Sensitivity Substrate, ThermoFisher) with Amersham ImageQuant 800
OD, according to manufacturer’s instructions (Cytiva, Marlborough, MA, USA). After imaging, pro-
tein signal intensity was quantified using ImageJ. All antibodies are listed in Key Resource Table.
Nuclear isolation from AML cells
Nuclear purifications were carried out per 100 million cells. Cells were collected by centrifugation at
400 x g for 5 min and washed in cold PBS. Washed cell pellets were resuspended in 15 mL hypotonic
buffer (10 mM HEPES pH 7.9, 10 mM NaCl, 1 mM MgCl2, 0.5 mM DTT, protease inhibitors) and
incubated on ice for 1 hr. Cells were lysed using 40 strokes by Dounce homogenization. Suspensions
were then centrifuged for 15 min at 3300 x g to pellet nuclei. Nuclear pellets were further purified
by sucrose density gradient centrifugation. Pellets were resuspended in 2.5 mL of 0.025 M Sucrose,
10 mM MgCl2 and layered on top of 2.5 mL 0.88 M sucrose, 0.05 mM MgCl2 and centrifuged for 10
min at 1200 x g. The final nuclear pellet was resuspended in 4 mL lysis buffer (50 mM Tris-HCl pH
7.4, 150 mM NaCl, 0.25 mM EDTA, 1 mM DTT, 0.5% Triton X-100, 10% glycerol, protease inhibitors)
and incubated on ice for 20 min. Nuclear suspensions were homogenized by 15 strokes in a Dounce
homogenizer without frothing, and clarified by centrifugation for 15 min at 18,000 x g. Clarified
lysates were immediately used for immunoprecipitations.
Co-immunoprecipitation
For MYB immunoprecipitations, 7.5 mg of anti-MYB antibodies (EP769Y, Abcam) were conjugated to
1 mg of M-270 Epoxy-coated magnetic beads (Invitrogen) according to manufacturer’s instructions.
For CBP immunoprecipitations, 50 mL of each of Protein A and Protein G Dynabeads (Invitrogen)
were combined and washed in 1 mL of PBS with 0.5% BSA. Fifteen mg of anti-CBP antibodies were
added to Protein A/G beads in 1 mL PBS with 0.5% BSA and incubated for 1 hr at room temperature
with rotation. Beads were then washed with 1 mL PBS with 0.5% BSA and beads were resuspended
in a final volume of 100 mL of PBS with 0.5% BSA. One hundred million cells were used per immuno-
precipitation. For displacement assays, cells were treated with 10 mM peptides as indicated for 1 hr
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at 37˚C in complete RPMI media prior to nuclear isolation. Immunoprecipitations were carried out
using 100 mL of respective antibody-bead slurry per immunoprecipitation overnight at 4˚C with rota-
tion. Beads were washed three times with 1 mL of cold lysis buffer. Proteins were eluted in 40 mL of
0.2 M glycine pH 3 for 30 min on a ThermoMixer (Eppendorf) at 900 rpm at room temperature. Elu-
ates were neutralized with 8 mL of 1 M Tris, pH 11. Samples were prepared for western blot by addi-
tion of western blot sample buffer described above together with 2.5 mL of 1M DTT and incubated
at 95˚C for 5 min.
Quantitative RT-PCR
Cells were treated as described above for cell viability assays for indicated times points. RNA was
isolated using RNeasy kit according to the manufacturer’s instructions (Qiagen). Complementary
DNA was synthesized using the SuperScript III First-Strand Synthesis system according to the manu-
facturer’s instructions (Invitrogen). Quantitative real-time PCR was performed using the KAPA SYBR
FAST PCR polymerase with 200 ng template and 200 nM primers, according to the manufacturer’s
instructions (Kapa Biosystems, Wilmington, MA, USA). Ct values were calculated by ROX normaliza-
tion using the ViiA seven software (Applied Biosystems).
Chromatin immunoprecipitation and sequencing
To prepare antibody-coupled beads, 30 mg of antibodies as indicated per ChIP were incubated with
1 mg of 1:1 Protein A/Protein G slurry in PBS with 0.5% BSA overnight at 4˚C with rotation. Beads
were washed twice in PBS with 0.5%. Fifty million cells were used per ChIP assay. Cells were fixed in
1% formaldehyde for 10 min at room temperature. Crosslinking was quenched by adding glycine to
a final concentration of 125 mM and incubating at room temperature for 5 min. Cells were pelleted
by centrifugation at 500 x g at 4˚C for 5 min. Cells were washed twice by resuspending 5 mL of PBS
with 1 mM PMSF and centrifuging at 500 x g at 4˚C for 5 min. Wash step was repeated twice. Cross-
linked pellets were resuspended in 2 mL of 50 mM Tris-HCl pH 8.1, 100 mM NaCl, 5 mM EDTA,
0.2% NaN3, 0.5% SDS, and protease inhibitors. Nuclei were pelleted by centrifugation at 15,000 x g
for 10 min at 4˚C. Pellets were resuspended in 50 mM Tris-HCl, 100 mM NaCl, 5 mM EDTA, 0.2%
NaN3, 0.3% SDS, 1.5% Triton X-100, and protease inhibitors and sonicated using the Covaris S220
adaptive focused sonicator at 5% duty Factor, 140W peak incident power, 200 cycles per burst for
30 min at 4˚C to obtain 100–500 base pair chromatin fragments (Covaris, Woburn, CA). Nuclear
sheared lysates were clarified by centrifugation at 15,000 x g for 10 min at 4˚C. Supernatants were
incubated with antibody-coupled Protein A/G beads as indicated overnight at 4˚C with rotation.
Beads were washed three times in 1 mL of 50 mM HEPES-KOH pH 7.6, 500 mM LiCl, 1 mM EDTA,
1% NP-40, 0.7% Na deoxycholate. For the final wash, 1 mL of 50 mM Tris-HCl pH 8, 10 mM EDTA,
50 mM NaCl was added to the beads. Beads were centrifuged for 3 min at 960 x g at 4˚C and super-
natant was removed. To elute, 210 mL of 50 mM Tris-HCl pH 8, 10 mM EDTA, 1% SDS was added to
the beads and incubated for 30 min at 65˚C. Beads were centrifuged for 1 min at 16,000 x g at room
temperature. Supernatant contains eluted samples. Crosslinks were reversed by incubation overnight
at 65˚C. Samples were diluted to 400 mL with 50 mM Tris-HCl pH 8, 10 mM EDTA, 50 mM NaCl, and
4 mL of 500 mg/ml RNase (Roche, Cat. No 11119915001) was added and incubated for 1 hr at 37˚ C
to digest RNA. Proteins were then digested by addition of 2 mL 20 mg/mL Proteinase K (Roche) and
incubation for 2 hr at 55˚ C. Samples were purified using PureLink PCR Purification Kit. Libraries
were prepared using the KAPA HTP Library preparation kit (Roche), according to the manufacturer’s
instructions, and sequenced on the Illumina HiSeq 2500 instruments, with 20–30 millions of 50 bp
paired-end reads for each sample.
For ChIP-seq analysis, reads were quality and adapter trimmed using ‘trim_galore’ before aligning
to human genome assembly hg19 with bowtie2 using the default parameters. Aligned reads with
the same start position and orientation were collapsed to a single read before subsequent analysis.
Density profiles were created by extending each read to the average library fragment size and then
computing density using the BEDTools suite. Enriched regions were identified using MACS 2.0 and
scored against matched input libraries. Genomic ‘blacklisted’ regions were filtered (http://www.
broadinstitute.org/~anshul/projects/encode/rawdata/blacklists/hg19-blacklist-README.pdf) and
remaining peaks within 500 bp were merged. Read density normalized by sequencing depth was
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then calculated for the union of peaks, and peak dynamics were assessed in DESeq2 using a fold
change of 1.5 and an FDR-adjusted p-value of 0.05.
RNA sequencing
Cells were treated with peptide or control in triplicate as described above for cell viability assays at
20 mM for 1 hr and 4 hr. Cells were collected and RNA was isolated using RNeasy kit (Qiagen)
according to manufacturer’s instructions. After RiboGreen quantification and quality control by Agi-
lent BioAnalyzer, 500 ng of total RNA underwent polyA selection and TruSeq library preparation
according to instructions provided by Illumina (TruSeq Stranded mRNA LT Kit), with 8 cycles of PCR.
Samples were barcoded and run on a HiSeq 4000 as PE100, using the HiSeq 3000/4000 SBS Kit (Illu-
mina). An average of 58 million paired reads was generated per sample. At most, ribosomal reads
represented 2.9% of the total reads generated and the percent of mRNA bases averaged 74%.
Reads were quality and adapter trimmed using ‘trim_galore’ before aligning to human assembly
hg19 with STAR v2.5 using the default parameters. Coverage and post-alignment quality were
assessed using the Picard tool CollectRNASeqMetrics (http://broadinstitute.github.io/picard/). Read
count tables were created using HTSeq v0.6.1. Normalization and expression dynamics were evalu-
ated with DESeq2 using the default parameters.
Genome annotations and gene expression estimation
The UCSC knownGene (Meyer et al., 2013), Ensembl 71 (Flicek et al., 2013), and MISO v.2.0
(Katz et al., 2010) annotations were combined into a single genome annotation. Gene expression
was estimated as previously described (Dvinge et al., 2014). RSEM v.1.2.4 (Li and Dewey, 2011)
was modified to invoke Bowtie v.1.0.0 (Langmead et al., 2009) through the ‘-v 2’ option in order to
map all reads to the merged genome annotation and obtain gene expression estimates. With
TopHat v.2.1.1 (Trapnell et al., 2009), the remaining unaligned reads were mapped to the human
genome (GRCh37/hg19) and a database of splice junctions. All expression estimates were normal-
ized via the trimmed mean of M values (TMM) method (Robinson and Oshlack, 2010).
Gene expression analyses
A minimum absolute log2(expression fold-change) requirement was selected to identify differen-
tially-expressed genes between CRYBMIM and PBS treatment, in the maximal number of AML cell
lines tested. Feasible thresholds were restricted to expression differences of at least 1.5-fold and
associated sample group comparison p-values<0.05. Unsupervised clustering on AML cell lines was
based on 41 genes which best separated the CRYBMIM- and PBS-treated samples (Figure 9—figure
supplement 1A). These genes were differentially expressed in at least four AML cell lines, with a
minimum absolute log2(expression fold-change)=0.794. Clustered gene expression heatmaps were
created with the pheatmap package (Kolde, 2020), using Ward’s minimum variance method and a
Euclidean distance for hierarchical clustering. For sample group comparisons of differential gene
expression, a two-sided t-test was used to determine statistical significance. Statistical analyses were
performed in the R programming environment with Bioconductor (Huber et al., 2015) and the dplyr
(Wickham et al., 2020) package. The associated figures were created using the ggplot2 (Wick-
ham, 2016) package.
Flow cytometry
MV411 cells were resuspended to a concentration of 1  106 cells per mL and plated in 12-well tis-
sue culture plates. To assess apoptosis, MYBMIM was used as a positive control and cells were
treated as described (Ramaswamy et al., 2018). Cells were treated with 20 mM CRYBMIM for 1 hr.
Following peptide treatment, cells were washed with PBS and resuspended with PBS with the addi-
tion of Annexin V-FITC (1:50) and CD11b (1:50). Cells were incubated on ice for 40 min followed by
two washes with cold PBS. DAPI was added prior to flow cytometric analysis (1:10,000).
Gene dependency analysis across cancer cell types
CRISPR knockout screen gene effect data from Project Achilles 19Q4 was downloaded from the
DepMap Consortium (DepMap, Broad (2019): DepMap 19Q4 Public Dataset doi:10.6084/m9.fig-
share.11384241.v2). Dependency scores for each gene were averaged by tumor type. A differential
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dependency score was then calculated as the relative difference between the average gene depen-
dency score for a tumor type and the average gene dependency score across all cell types. All genes
were then ranked by leukemia gene differential dependency scores, and the top 10 and bottom 10
leukemia gene dependencies were plotted as a heat map. p-Values were calculated comparing MYB
dependency in leukemias versus all other tumor types using two-tailed t-test.
Mass spectrometry proteomics
Immunoprecipitations were carried out as described above in biological triplicates. Eluates were
resolved by SDS-PAGE 10% polyacrylamide Bis-Tris gels (Invitrogen) at 100 V for 5 min. To visualize
proteins, gels were stained using Silver Stain for Mass Spectrometry kit (Pierce) according to manu-
facturer’s instructions. Relevant gel portions were excised and destained using 50 mL of 30 mM
K3[Fe(CN)6] in 100 mM aqueous Na2S2O3 by incubation at room temperature for 30 min, with gentle
mixing halfway through. Following destaining, 500 mL of 25 mM aqueous NH4HCO3 were added to
each tube and incubated for 5 min at room temperature on a ThermoMixer (Eppendorf) at 700 rpm.
Solution was removed and gel pieces were washed by adding 500 mL of 50% acetonitrile in 25 mM
aqueous NH4HCO3 and incubating for 10 min at room temperature on a ThermoMixer at 700 rpm.
Wash step was repeated two more times. All solution was removed and 100 mL of acetonitrile was
added to each tube and incubated for 5 min at room temperature on a ThermoMixer (Eppendorf) at
700 rpm. All solution was removed and destained gel fragments were vacuum centrifuged and
stored at  20˚C. For reduction of disulfide bonds, gel fragments were re-hydrated in 25 mL of 10
mM dithiothreitol in 100 mM aqueous NH4HCO3 for 1 hr at 56˚C. Tubes were cooled to room tem-
perature. For alkylation of thiols, 25 mL of 55 mM iodoacetamide in 100 mM aqueous NH4HCO3 was
added to each tube and incubated for 30 min at room temperature in the dark. To quench the alkyl-
ation reaction, 5 mL of 100 mM dithiothreitol in 100 mM aqueous NH4HCO3 was added and incu-
bated for 5 min at room temperature. Gel fragments were washed by adding 50 mL of acetonitrile
and incubation for 5 min at room temperature followed by addition of 500 mL of 100 mM aqueous
NH4HCO3 and incubation for 10 min at room temperature. All solution were removed and wash step
was repeated. All solution were removed and 100 mL of acetonitrile was added and tubes were incu-
bated for 10 min at room temperature. All solution were removed and gel fragments were vacuum
centrifuged and stored at  20˚C. For digestion of proteins into peptides, gel fragments were cooled
on ice. Protease LysC was added at a ratio of 1:25 protease:protein, assuming 1 mg of protein per
immunoprecipitation. Gel fragments were incubated for 5 min on ice. Samples were diluted to 50
mL, or to cover gel fragments using 50 mM aqueous NH4HCO3. Digestion was carried out for 4 hr at
37˚C. Following LysC digestion, trypsin was added to each tube at the 1:25 protease:protein ratio in
50 mM aqueous NH4HCO3. Trypsin digestion was carried out for 16 hr at 37˚C. To elute peptides
from gel fragments, 50 mL of 1% formic acid in 70% acetonitrile was added to each tube and incu-
bated for 30 min at room temperature on a ThermoMixer at 1400 rpm. Eluates were removed and
saved, and elution step was repeated with fresh 1% formic acid in 70% acetonitrile. New eluates
were pooled with the first elution for a total of 100 mL of eluate per sample. Samples were vacuum
centrifuged to dryness. Prior to mass spectrometry analysis, samples were desalted and purified by
solid phase extraction using C18 Micro SpinColumns (Nest Group) and eluted with 70% acetonitrile
supplemented with 0.1% formic acid. Eluates were vacuum centrifuged to remove all solution. Sam-
ples were resuspended in 8 mL of 0.1% aqueous formic acid and sonicated for 5 min to ensure full
resuspension. Three mL of each sample were used for mass spectrometry analysis.
The LC system used a vented trap-elute configuration (EasynLC1000, Thermo Fisher scientific)
coupled to an Orbitrap Lumos mass spectrometer (Thermo Fisher Scientific, San Jose, CA) via a
nano electro-spray DPV-565 PicoView ion source (New Objective). The trap column was fabricated
with a 5 cm  150 mm internal diameter silica capillary with a 2 mm silicate frit, and pressure loaded
with Poros R2-C18 10 mm particles (Life Technologies). The analytical column consisted of a 25
cm  75 mm internal diameter column with an integrated electrospray emitter (New Objective),
packed with ReproSil-Pur C18-AQ 1.9 mm particles (Dr. Maisch). Peptides were resolved over 90 min
using a 3–45% gradient of acetonitrile with 0.1% aqueous formic acid at 250 nL/min.
Precursor ions in the 375–3000 m/z range were isolated using the quadrupole and recorded every
3 s using the Orbitrap detector (60,000 resolution, with 445.1200 ions used as lockmass), with an
automatic gain control target set at 106 ions and a maximum injection time of 50 ms. Data-depen-
dent precursor ion selection was enforced, limiting fragmentation to monoisotopic ions with charge
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2–5 and precursor ion intensity greater than 5  104, and dynamically excluding already fragmented
ions for 30 s (10 ppm tolerance). Selected ions were isolated (Q1 isolation window 0.7 Th) and frag-
mented using HCD (normalized collision energy 30) using the top speed algorithm. Product ion
spectra were recorded in the Orbitrap at 30,000 resolution (AGC of 8  104 ions, maximum injection
time 54 ms), in profile mode.
Mass spectra were analyzed using MaxQuant (version 1.6.0.16). For identification, spectra were
matched against the human UniProt database (as of October 2017), supplemented with contaminant
proteins from the cRAP database with FDR < 0.01. After m/z recalibration, mass tolerance was set at
4.5 and 20 ppm for precursor and fragment ions, respectively. Cysteine carbamidomethylation was
set as fixed chemical modification, while methionine oxidation and protein N-terminus acetylation
were set as variable. Protease specificity was set to trypsin/P, with up to two missed cleavages
allowed. The match between runs feature was enabled (0.7 min tolerance, 20 min alignment). Quan-
tification was performed using the LFQ algorithm.
Contaminating peptides such as keratin and non-human proteins were excluded and label-free
quantification (LFQ) intensity values for protein groups were used for analysis. IgG and MYB immu-
noprecipitation samples were analyzed together (three replicates per condition; six samples total).
Proteins in the following categories were excluded from analysis: (i) zero LFQ intensity across all rep-
licates, (ii) zero LFQ intensity in five of six replicates, (iii) proteins with LFQ intensity recorded in only
one replicate in both sets of samples. Enrichment scores were defined as the log2 ratio of MYB:IgG.
Statistical analysis, principal component analysis, and hierarchical
clustering
OriginPro 2018 (Origin Lab) was used for statistical analysis. Principal component analysis was per-
formed using prcomp (R Studio). The hierarchical cluster analysis was carried out with R function
pheatmap with Pearson’s distance as the distance metrics and ‘average’ as the clustering method.
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Appendix 1
Appendix 1—key resources table






Cell line (Homo-sapiens) MV411 ATCC Cat# CRL-9591,
RRID:CVCL_
0064
Cell line (Homo-sapiens) MOLM13 DSMZ Cat# ACC-554,
RRID:CVCL_
2119
Cell line (Homo-sapiens) OCIAML2 DSMZ Cat# ACC-99,
RRID:CVCL_
1619
Cell line (Homo-sapiens) THP1 ATCC Cat# TIB-202,
RRID:CVCL_
0006
Cell line (Homo-sapiens) NB4 DSMZ Cat# ACC-207,
RRID:CVCL_
0005




Cell line (Homo-sapiens) HEL ATCC Cat# TIB-180,
RRID:CVCL_
2481
Cell line (Homo-sapiens) OCIAML3 DSMZ Cat# ACC-582,
RRID:CVCL_
1844
Cell line (Homo-sapiens) SKM1 DSMZ Cat# ACC-547,
RRID:CVCL_
0098




Cell line (Homo-sapiens) HL60 ATCC Cat# CCL-240,
RRID:CVCL_
0002
Cell line (Homo-sapiens) K562 ATCC Cat# CCL-243,
RRID:CVCL_
0004
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Appendix 1—key resources table continued
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Appendix 1—key resources table continued
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Commercial assay or kit CD34 MicroBead Kit
UltraPure, human
Miltenyi Biotech 130-100-453
Commercial assay or kit Dynabeads Antibody
Coupling Kit
Thermo Fisher 14311D
Chemical compound, drug Doxorubicin Sigma Aldrich D1515












Continued on next page
Takao, Forbes, Uni, et al. eLife 2021;10:e65905. DOI: https://doi.org/10.7554/eLife.65905 43 of 46
Research article Cancer Biology
Appendix 1—key resources table continued










Software, algorithm MAGeCK Li et al., 2014 RRID:N.A. Genome-wide
CRISPR screen


































Software, algorithm HTSeq v0.6.1. Anders et al.,
2014




















































Software, algorithm R programming
environment
with Bioconductor














Software, algorithm RStudio RStudio RRID:SCR_
000432
Statistical analysis
Software , algorithm ImageJ Fiji RRID:SCR_
002285
Image processing
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Appendix 1—key resources table continued














All supplemental data are available openly via Zenodo (https://doi.org/10.5281/zenodo.4321824).
Mass spectrometry proteomics data are available via PRIDE (PXD019708). Gene expression and
chromatin dynamics data are available via Gene Expression Omnibus (GSE163470).
Lists of supplemental data deposited in zenodo
MYBMIM Genome-wide CRISPR screen (Figure 1)
01_MYBMIM_GeCKO_gene_summary.xlsx Genome-wide GeCKO CRISPR screen in MYBMIM
treated MOLM13 cells
02_Control_GeCKO_gene_summary.xlsx Genome-wide GeCKO CRISPR screen in PBS treated
MOLM13 cells
RNA-seq and GSEA with CRYBMIM and CREBMIB (Figure 5)
03_RNAseq_DESeq2_CRYBMIM_1hr-vs-PBS_1
hr_SignificantAll.xlsx
Excel file of differentially expressed genes measured by
RNA-seq in 1 hr CRYBMIM vs PBS treated MV411
04_RNAseq_DESeq2_CRYBMIM_4hr-vs-PBS_4
hr_SignificantAll.xlsx
Excel file of differentially expressed genes measured by
RNA-seq in 4 hr CRYBMIM vs PBS treated MV411
05_RNAseq_DESeq2_CREBMIM_1hr-vs-PBS_1
hr_SignificantAll.xlsx
Excel file of differentially expressed genes measured by
RNA-seq in 1 hr CREBMIM vs PBS treated MV411
06_RNAseq_DESeq2_CREBMIM_4hr-vs-PBS_4
r_SignificantAll.xlsx
Excel file of differentially expressed genes measured by
RNA-seq in 4 hr CREBMIM vs PBS treated MV411
07_gsea_report_for_na_pos_1552361301359_CRYBMIM-
vs-PBS_1 hr.xlsx
Gene set enrichment analysis for differentially
expressed genes measured by RNA-seq in 1 hr
CRYBMIM vs PBS (positive enrichment)
08_gsea_report_for_na_neg_1552361301359_CRYBMIM-
vs-PBS_1 hr.xlsx
Gene set enrichment analysis for differentially
expressed genes measured by RNA-seq in 1 hr
CRYBMIM vs PBS (negative enrichment)
09_gsea_report_for_na_pos_1552361302266_CRYBMIM-
vs-PBS_4 hr.xlsx
Gene set enrichment analysis for differentially
expressed genes measured by RNA-seq in 4 hr
CRYBMIM vs PBS (positive enrichment)
10_gsea_report_for_na_neg_1552361302266_CRYBMIM-
vs-PBS_4 hr.xlsx
Gene set enrichment analysis for differentially
expressed genes measured by RNA-seq in 4 hr
CRYBMIM vs PBS (negative enrichment)
11_gsea_report_for_na_pos_1552361302042_CREBMIM-
vs-PBS_1 hr.xlsx
Gene set enrichment analysis for differentially
expressed genes measured by RNA-seq in 1 hr
CREBMIM vs PBS (positive enrichment)
12_gsea_report_for_na_neg_1552361302042_CREBMIM-
vs-PBS_1 hr.xlsx
Gene set enrichment analysis for differentially
expressed genes measured by RNA-seq in 1 hr
CREBMIM vs PBS (negative enrichment)
13_gsea_report_for_na_pos_1552361302044_CREBMIM-
vs-PBS_4 hr.xlsx
Gene set enrichment analysis for differentially
expressed genes measured by RNA-seq in 4 hr
CREBMIM vs PBS (positive enrichment)
14_gsea_report_for_na_neg_1552361302044_CREBMIM-
vs-PBS_4 hr.xlsx
Gene set enrichment analysis for differentially
expressed genes measured by RNA-seq in 4 hr
CREBMIM vs PBS (negative enrichment)
Continued on next page
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continued
MYBMIM Genome-wide CRISPR screen (Figure 1)
ChIP-seq analysis for MYB and CBP
(Figures 6 and 11)
15_ChIPseq_DESeq2_Named_Significant
Increase_All_CRYBMIM-vs-PBS_1 hr_MYB.xlsx
Differentially increased peaks measured by MYB ChIP-
seq in 1 hr CRYBMIM vs PBS treated MV411
16_ChIPseq_DESeq2_Named_Significant
Decrease_All_CRYBMIM-vs-PBS_1 hr_MYB.xlsx
Differentially decreased peaks measured by MYB ChIP-
seq in 1 hr CRYBMIM vs PBS treated MV411
17_ChIPseq_DESeq2_Named_Significant
Increase_All_CRYBMIM-vs-PBS_1 hr_CBP.xlsx
Differentially increased peaks measured by CBP ChIP-
seq in 1 hr CRYBMIM vs PBS treated MV411
18_ChIPseq_DESeq2_Named_Significant
Decrease_All_CRYBMIM-vs-PBS_1 hr_CBP.xlsx
Differentially decreased peaks measured by CBP ChIP-
seq in 1 hr CRYBMIM vs PBS treated MV411
19_ChIPseq_DESeq2_Named_Significant
Increase_All_CRYBMIM-vs-PBS_4 hr_MYB.xlsx
Differentially increased peaks measured by MYB ChIP-
seq in 4 hr CRYBMIM vs PBS treated MV411
20_ChIPseq_DESeq2_Named_Significant
Decrease_All_CRYBMIM-vs-PBS_4 hr_MYB.xlsx
Differentially decreased peaks measured by MYB ChIP-
seq in 4 hr CRYBMIM vs PBS treated MV411
21_ChIPseq_DESeq2_Named_Significant
Increase_All_CRYBMIM-vs-PBS_4 hr_CBP.xlsx
Differentially increased peaks measured by CBP ChIP-
seq in 4 hr CRYBMIM vs PBS treated MV411
22_ChIPseq_DESeq2_Named_Significant
Decrease_All_CRYBMIM-vs-PBS_4 hr_CBP.xlsx
Differentially decreased peaks measured by CBP ChIP-
seq in 4 hr CRYBMIM vs PBS treated MV411
MYB and CBP IP-MS data (Figure 7)
23_IP-MS_MYB_IgG_protein list.xlsx List of proteins identified by IP-MS of IgG control and
MYB complex purifications from MV411 cell nuclei
24_IP-MS_CBP_IgG_protein_list.xlsx List of proteins identified by IP-MS of IgG control and
CBP complex purifications from MV411 cell nuclei
RNA-seq analysis with CRYBMIM in 5 AML
cell lines (Figure 9—figure supplement 1)
25_RNAseq_expression_all_coding_5AML_celllines.xlsx All coding gene expression changes measured by
RNA-seq in 1 hr CRYBMIM vs PBS treated MV411, HL-
60, Kasumi-1, OCI-AML3 and U937
ChIP-seq anaysis for multiple TFs (Figure 11)
26_ChIPseq_DESeq2_FilteredNormalized
Counts_PeakNorm_CRYBMIM-vs-PBS_1 hr_allTFs.xlsx
Differentially increased peaks measured by multiple TF
ChIP-seq in 1 hr CRYBMIM vs PBS treated MV411
27_ChIPseq_pathway_analysis_9 clusters.xlsx Pathway analysis for 9 clusters of transcription factor-
remodeled genes measured by ChIP-seq
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